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Rationale and structure of the conference  
Razionale e struttura della Conferenza
Claudio F. Donner  
Mondo Medico, Multidisciplinary and Rehabilitation Outpatient Clinic, Borgomanero (NO), Italy
Chronic respiratory diseases (CRDs), with particular
regard to COPD, constitute an epidemic in the full
sense of the term, though they still go underdiag-
nosed and undertreated. COPD is one of the major
health problems worldwide, negatively affecting
patients and their families, the employment sector,
the institutional network and, hence, society as a
whole. Its epidemiological, clinical, social and
socio-economic impact is on the rise and there are
no signs of any change to this trend. 
The Global Alliance against chronic Respiratory
Diseases (GARD) of the World Health Organisation
(WHO) - of which AIMAR has been a partner since
2005 [1] - was launched in 2006 as “a voluntary
alliance of national and international organizations,
institutions and agencies committed to the vision of
a “world where all people can breathe freely” [2,3].
The goal of GARD is to improve global lung health
by promoting a comprehensive approach to fight
CRDs within the framework of the WHO strategic
measures [4]. 
GARD has formulated the following working re -
commendations: 
- to develop national programs of prevention and
control of CRDs, with the double aim of defining


























actions and raising political and social awareness
about this public health priority. The first step to
attain this goal are health education campaigns
and data collection on: the frequency of these dis-
eases, their impact, and the relative risk factors;
- to provide training and continuing education on
prevention and treatment of CRDs, disseminating
the existing guidelines; 
- to facilitate access to essential treatments and
favour adherence to long term treatment, includ-
ing drug treatment and pulmonary rehabilitation,
particularly amongst disadvantaged sectors of the
population. 
Besides GARD recommendations to create syner-
gies on prevention and control between CRDs and
other chronic diseases, the final outcome should be
country-specific initiatives tailored to local needs.
Therefore, after the first phase, from 2006 to 2008,
devoted to building a global network, consolidating
objectives and creating tools and resources, the sec-
ond phase (started in 2008 and due to end in 2015)
has as its aim to launch GARD national organiza-
tions in each country [5]. 
Pre-requisites for developing a GARD national body
are as follows:
1. a prior analysis of the situation of surveillance,
prevention and control of chronic respiratory dis-
eases in that country; 
2. invitation to the Ministry of Health to participate
in the development of the GARD national body;
3. a similar invitation to the WHO Regional Office
and WHO country representative.
In Italy, all three pre-requisites were fulfilled in June
2009 when GARD-Italy was launched in Rome,
during a meeting addressed by the Minister of
Health, Ferruccio Fazio [6] in which a Document of
Strategy [7] was signed by all the major medical
and patients’ societies and associations attending
the meeting. AIMAR signed this document and
viewed it as the first endpoint of numerous initiatives
carried out by AIMAR to implement GARD in Italy
(seminars, learning courses, conferences, docu-
ments, recommendations, all aimed at emphasising
the importance of respiratory diseases and dissemi-
nating the existing guidelines for their management).
Among the actions which a GARD national body is
urged by WHO-GARD to carry out, one is to re -
commend affordable and effective strategies for the
management of CRDs based on the latest evidence
[8]. Another is to provide training and continuing
education on the prevention and treatment of
CRDs, disseminating the existing guidelines, while
emphasizing the sustainability of all the recom-
mended actions. 
In face of the need to reconcile the limited available
economic resources with the increasing demand for
well-being, the health services of industrialized
countries are at present devoting much attention to
the costs generated by healthcare in their own terri-
tories. CRDs, in particular, concern a large number
of subjects and generate important health and
social costs. The global impact of these diseases, in
particular COPD, has been the subject of an
increasing number of pharmaco-economic studies
published in the literature in recent years. Although
these studies had different experimental designs,
they all confirm the growing impact of COPD in all
countries, both from the perspective of the patient
and patient’s family, and that of society as a whole.
The findings that emerge reveal that the attitude
towards COPD management is still largely inadequate.
This Top Seminar, starting from the above scenario,
focuses on the role that the pulmonary specialist
can play in detecting inappropriateness in the clin-
ical course of COPD and in providing the basis for
a correct assessment of pharmaco-economic issues.
Given the increasing social impact of COPD, the
meeting fits in perfectly with the goals and recom-
mendations of GARD.
“COPD a social disease: inappropriateness and
pharmaco-economics. The role of the specialist:
present and future” has been organized by AIMAR
under the umbrella of the ‘Year of the Lung 2010’
promoted worldwide by the Forum of International
Respiratory Societies and within Europe by the
European Respiratory Society. AIMAR has designed
this new Top Seminar as a moment for all the stake-
holders (Ministry of Health, health district man-
agers, patient organizations and specialists in respir -
atory medicine) to come together and reflect on the
pharmaco-economic issues related to the clinical
course of COPD. 
The Seminar will be divided into four sessions: 
1. From scientific to social and institutional recogni-
tion: comparing different experiences.
2. Pharmaco-economics.
3. Inappropriateness at different steps of management.
4. A new decade of COPD. 
In each session, leading international scholars of
COPD will discuss with the other stakeholders not
only the scientific issues, but also the impact - pres-
ent and future - of COPD from the point of view of
the patient, their family and society as a whole. The
Seminar will produce a series of documents (e.g. a
short report to be published in Respiratory
Medicine, and full proceedings in Multidisciplinary
Respiratory Medicine, AIMAR’s official journal)
which will be useful for GARD-I to plan and imple-
ment actions so as to make Italy a country “where
all people can breathe freely”.
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Future of NHS in the welfare state  
Il futuro del Servizio Sanitario Nazionale nel “welfare state”  
Maurizio Sacconi  
Minister of Labour and Welfare, Rome, Italy
The National Health Service (NHS) has up till now
guaranteed health care to all citizens along with a
constant rise both of the average life expectancy
and of individual wellbeing. In a certain sense,
however, the NHS is today a victim of its own self:
in the last fifty years – following progress in medi-
cine and in the organization of the social state –
Italy (as other developed countries) has seen a rad-
ical change in what constitute the prevalent dis-
eases and main causes of death, and this change
has thrown the NHS into crisis. The chronic invali-
dating diseases that dominate the scene today can-
not be managed with the old hospital-centered
model that was based on the need to respond to
acute situations: the system has to be readapted to
the actual epidemiological situation today.
The health care provided for chronic broncho -
pulmonary diseases, lung cancer and cancer in gen-
eral, for diabetes and heart diseases (to mention just
a few of the most frequent and important diseases)
is becoming increasingly costly (as new pharmaco-
logical and rehabilitative therapies are introduced
and patients survive longer) and the number of peo-
ple affected by these diseases is destined to rise sub-
stantially as the average age of the population rises.
These tendencies could in the medium term render
the cost of health unsustainable and, in the absence
of corrective re-equilibrating measures, health costs
might more than double by 2050. For this reason a
radical change in the organization of the NHS is
necessary, in harmony with a change in the role
played by the state. 
In the 19th and first part of the 20th century, the
prevalent diseases were infective diseases of an epi-
demic nature (such as cholera, tuberculosis,
poliomyelitis) and the role of the state was in the
first place to guarantee drinkable water, sewage dis-
posal and improved living conditions, and success-
ively to help defend the population through pro-
grams of mass vaccination against diseases not
eliminated by the improved public hygiene. Today
the diseases are linked to life styles chosen on an indi-
vidual basis, not to collective living conditions, and
hence the role of the state is no longer to choose and
implement the best health options on behalf of citi-
zens but rather to help citizens themselves choose the
best options, through education, health information
and the provision of integrated services of primary,
secondary and tertiary prevention.
The future of the NHS will thus be focused on pri-
mary prevention (helping citizens to prevent the
onset of diseases) and early diagnosis and rehabili-
tation (helping citizens to reduce the invalidating
consequences of already existing diseases with the
least possible impact on the community). It goes
without saying that the need for a radical change in
health care for reasons of sustainability, already
announced in previous years, has now become
absolutely urgent with the heavy crisis that has
recently hit the world economy. 
These changes in the NHS will take place within the
context of an overall change in the whole welfare
system, centered on the idea that people first try to
develop their own resources to respond to their
needs, that people live in a free and responsible
manner and respond to their own uncertainties. In
other terms, in the new welfare, the concession of
protection and subsidies will be subject, where pos-
sible, to the citizen’s active participation in society
through a path that ensures opportunities while
stimulating the individual’s own responsibility. 
The link between health and social wellbeing is
indissoluble: just as health promotion reduces
poverty, emargination and social distress and
increases work productivity, employment rates and
overall economic growth, so too does an increase
in the quality of work and work opportunities over
a longer life span, and a context that favours
employability and social mobility - whatever the
individual’s starting point - translate into greater
health and psycho-physical wellbeing. The new
welfare must orient people towards active behav-
iours and responsible lifestyles, preventing situa-


























ty, old age) or pathological (disease, accident, dis-
ability) events or to particular economic situations
(business or employment crises, unemployment,
termination of work). In this context, health does
not mean simply treating the disease but rather a
priori promoting wellbeing and developing person-
al capacities, taking into account the different con-
ditions of each individual. 
The citizen’s active participation, a correct informa-
tion and health culture, essential in an era of great
changes, a renewed relationship of trust between
family doctor and patient, are the premises for pro-
moting healthy life in the active society (which also
is – not by chance – the title of the white book on
the future of the social model recently produced by
the Ministry. The physical setting in which the
changes described above will take place is the local
community, i.e. the place where the integrated,
preventive responses to people’s real and potential
needs are put into effect, where the policies
designed to guarantee the continual employability
of people are implemented, so preventing their
exclusion from the employment market; and, final-
ly, where the social-health services aimed at pre-
vention, early diagnosis, primary care, and home
care are developed. 
What will have to be achieved as rapidly as possible
is a unified management of the homogeneous
socio-health-welfare services at local level, able to
create a continuum between systems for health care
and those for social protection; a unified manage-
ment that sees the socio-health districts as the citi-
zens’ center of reference and the place where this
integration occurs in effect.
In the NHS, one will have to go beyond the concept
of “integration” between hospital and local com-
munity in favour of a new interdisciplinary and
interprofessional approach with the person at the
center of the treatment process (which must flow
without interruptions), utilizing a personal electron-
ic dossier that contains all relevant information
about the person. In this vision, the hospital will
return to its “historical” role as a provider of emer-
gency and acute care while the general practitioner
(GP), operating no longer as a “soloist” but in asso-
ciation with other professionals in a collaborative
network, will be the stable point of reference for the
patient throughout the course of the day and week.
Addressing an international audience of respiratory
specialists, I cannot but conclude with some
remarks of particular reference to specialists,
focused on the application of the new model of
welfare to respiratory medicine. I greatly appreciate
the fact that the title of your Seminar is related to the
“social” aspects of the most important chronic res-
piratory disease and that you particularly wish to
examine the specialist’s role in the appropriateness
of interventions and in the “pharmaco-economics”
of management.
Respiratory diseases constitute an emergency. In
Italy, all together (including also lung cancer) they
represent the second most important cause of death
and their frequency and diffusion is probably far
greater than we actually realize, given that they are
widely under-diagnosed. Underdiagnosis has not
only epidemiological but also clinical conse-
quences: as little attention is paid to respiratory dis-
eases by the individual and by the community,
those affected receive late and non optimal treat-
ment. A further consequence of the poor visibility
that up to now has characterized respiratory dis-
eases is that insufficient consideration is given to
the specialist hospital structures dedicated to them.
However, signs of the new importance now being
attributed to respiratory diseases are the fact that the
Italian National Health Plan 2006-2008 placed
chronic respiratory diseases among its four top
health priorities and that the Ministry of Health
launched in 2009 - when I myself was Minister of
Health - GARD-Italy, the Italian part of the Global
Alliance against Chronic Respiratory Diseases
(GARD) of the World Health Organization (WHO),
a volountary alliance of national and international
organizations, institutional bodies and agencies that
has as its goal to reduce the global burden of chron-
ic respiratory diseases. 
It is precisely this recognized importance that
prompts us to denounce the critical situation that
exists at present. Patients suffering from chronic pul-
monary diseases are treated in a discontinuous and
non integrated mode: this leads to inappropriate-
ness of the caring procedures. This inappropriate-
ness represents a cost that is not negligible. The
Institute for the Innovation and Improvement of the
NHS in Britain evidenced, for example, that GBP
£1.3 billion are spent each year in visits to
Emergency Care for patients with 18 diseases
(www.healthcarecommission.gov.uk). 
These include up to three or four visits per year by
the same patient. Not by chance, occupying first
place in the list of diseases is chronic obstructive
pulmonary disease (COPD), with more than
106,000 admissions and an annual cost of £253
million, while in third place, after angina pectoris,
comes asthma with more than 61,000 admissions
and a cost of £64 million. Varying percentages of
these admissions resulted inappropriate at a retro-
spective analysis. An optimal management of the
above diseases would not only reduce the crowding
of Emergency Care facilities and lower the global
health costs, but it would improve also the condi-
tions of life of those affected. 
At the organizational level, the health care for
chronic respiratory diseases will be similar to that
for diabetics. One must achieve a greater possibility
of self management for the patient, give more
responsibility to the GP, with an opportune use of
telemedicine and home care built into the plan.
In the field of pulmonology, the NHS must under-
take in each ULSS to:
1. prevent respiratory disease developing through a
consistent reduction of the number of smokers in
the community;
2. improve COPD diagnosis, in particular through a
more widespread use of spirometric tests;






























0 through pulmonary rehabilitation;
4. integrate the care of patients affected by COPD,
i.e. link specialist care to primary care, and
extend end of life treatment from the oncological
to the respiratory sphere.
Within the strictly hospital setting, the role of
Pneumology will be similar to that of modern cardi-
ology: intensive management of acute respiratory
problems and consultancy and specialist guidance
provided within the local community. In terms of
this project each Operational Unit will have to
organize itself.
On this subject, I would like to cite an experiment
that is underway in the area I come from. It is an ini-
tiative in pulmonary rehabilitation on patients
affected by COPD, which involves, besides respira-
tory specialists and GPs, also sports physicians and
graduates in motor science. This initiative is being
carried out completely in the local community and
has so far enrolled 50 patients, who have been
offered the possibility of strength re-education.
What is news for you who are specialists in the field
is not so much the fact that all the participants have
increased their performance and improved their
quality of life, but that this has all occurred through
a multidisciplinary effort and completely outside of
the hospital setting.
I hope that this Seminar will bring other significant
gains to help individual specialists better under-
stand the existing problems and better define their
own role.
The growing role of rehabilitation and chronic care  
Il ruolo crescente della riabilitazione e del trattamento cronico  
Daniela Carraro  
General Manager, Health & Social Welfare District 21, Legnago (VR), Italy
Definition and background
Pulmonary rehabilitation is an evidence-based,
multidisciplinary and comprehensive intervention
for patients with chronic respiratory diseases who
are symptomatic and often have decreased daily life
activities. Integrated into the individualized treat-
ment of the patient, pulmonary rehabilitation is
designed to reduce symptoms, optimize functional
status, increase participation, and reduce health
care costs through stabilizing or reversing systemic
manifestations of the disease [1].
Extensive rehabilitation: “Complex welfare activity
for patients who have superceded the acute and
immediate post-acute phase and require interven-
tions to ensure further functional recovery in a
defined time” (DRG 398/2000).
Rehabilitative maintenance activities: “Assistance
activities aimed at patients with stabilized outcome
from psycho-physical disease requiring interven-
tions to keep any residual capacity functional or to
contain the damage” (DRG 398/2000).
Aim
Specific aims of pulmonary rehabilitation are to
reduce symptoms, teaching patients to deal success-
fully with their disease, to maintain an active and
independent lifestyle, to maximize functional abilities,
to reduce the consumption of healthcare resources
and, where possible, to improve survival [2-4].
Materials and methods
Pulmonary rehabilitation programs involve patient
assessment, exercise training, education, nutritional
intervention and psychosocial support. Pulmonary
rehabilitation includes a spectrum of interventional
strategies integrated into the lifelong management
of patients with chronic respiratory disease and
involves a dynamic, active collaboration among the
patient, family and health care providers. These
strategies address both the primary and the second-
ary impairments associated with the respiratory dis-
ease [1].
The rehabilitation program includes optimizing the
drug therapy, education, chest physiotherapy, exer-
cise training, respiratory muscle training, selective
muscle group training, occupational therapy, reduc-
ing workload of the respiratory muscles, long-term
oxygen therapy, psychosocial and nutritional pro-
grams [5,6].
These programs are aimed at patients with the fol-
lowing diseases: COPD, asthma, cystic fibrosis,
bronchiectasis, chronic respiratory failure (CRF)
from any cause, severe acute respiratory patients
with CRF, restrictive syndromes from neuromuscu-
lar and chest wall diseases, pulmonary fibrosis and
other interstitial disease, pre- and post-surgery, 
outcomes of chest injury, respiratory sleep disor-
ders, outcomes of pulmonary embolism, chronic
pulmonary heart disease, preparation and manage-
ment of lung transplantation [7-9].
Pulmonary rehabilitation programs can be per-
formed:
- at home: usually they follow the inpatient and out-
patient programs; interventions are designed to
keep the patient at the highest level of sufficiency;
- in day hospital and/or the outpatient setting:


























ed by the subject consequent to an acute event;
- in hospital: patients with no or limited mobility
who need continuous monitoring and invasive
maneuvers, or with transport difficulties. 
An example: COPD (Figure 1).
Patients with COPD are a group of high consumers
of healthcare resources in terms of drugs, hospital
admissions and days spent in hospital: in a study
conducted in Italy on moderate to severe COPD
patients hospitalized due to exacerbation, health
care rehabilitative treatment was only €42 per
patient/year, i.e. 0.9% of all direct costs. Despite
this, one of the potential benefits of rehabilitation
would be to reduce episodes of exacerbations and,
as a result, health spending [9-10].
Rehabilitation programs have been shown to
reduce hospitalizations and home visits and the
number of exacerbations [11]. Clini has demon-
strated that a cycle of rehabilitation included in a
shorter hospitalization stay resulted in the same
physiological effects as a longer cycle in day-hospi-
tal, but had lower costs [12].
Organization, setting
While many protocols have been evaluated to ren-
der respiratory rehabilitation more efficient in vari-
ous lung diseases, few studies have focused on the
optimal composition of the staff, organization of the
place of care and equipment [13]. Respiratory rehab -
ilitation is a multidisciplinary intervention, in which
the following health professionals collaborate:
- pulmonologist, who should have the role of pro-
gram director
- nursing staff
- rehabilitation therapists (nine different types re -
commended). 
Areas of rehabilitation treatment and types of
patients:
1. Respiratory Intensive Care Unit and general ICU
2. Pulmonary diseases department
3. Pulmonary rehabilitation in pre- and post-tho-
racic and abdominal surgery
4. Pulmonary rehabilitation in pre- and post-trans-
plant of thoracic and abdominal organs (lung,
heart, liver, etc.)
5. Respiratory rehabilitation in diseases character-
ized by muscle weakness (neuromuscular disor-
ders)
6. Respiratory disease in children [14].
Existing models
At present the organizational models and the rehab -
ilitation programs are not very uniform. 
1. The model used in some foreign countries (USA,
Canada, Brazil) and in some Italian hospitals is
that physiotherapists form a functional team with
the other professionals; they are always present,
in ICU and in the Emergency Room, covering the
entire day, every day of the week and (only
abroad) with shifts even at night. 
2. Another organizational model, often found in
Italy, provides for the presence of physiotherapists
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0 entire hospital, especially if this is dedicated to
specific diseases. Here the physiotherapist carries
out his/her duties, often working alongside other
professionals with activities during the day for 5
days/week. These structures also provide out -
patient treatment for external or discharged
patients (e.g. regional centers for cystic fibrosis
and other centers dedicated to pediatric, orthope-
dic, neuromuscular disease, and many rehabilita-
tion centers in agreement with the National
Health System). 
3. A third model envisages a pyramid structure, in
which physical therapists address all needs; it
provides all the benefits of rehabilitation "on
demand" as requested by the other operating
units. Rehabilitation treatment is interrupted
when the patient is discharged, and the physio-
therapist moves on to deal with a new case that
is assigned [14].
Results and conclusions
Pulmonary rehabilitation is undergoing great devel-
opment. Since the publication of previous recom-
mendations there has been significant progress in
both techniques and outcome assessment [13]. The
new data give further support for:
- the benefits of training in improving lower limb
dyspnea and quality of life. There are no definitive
studies on the effect on survival, costs and utiliza-
tion of resources;
- other studies have evaluated upper limb training
as a means to obtain benefits in daily living activ-
ities, but the results do not offer sufficient evi-
dence for its introduction as a routine practice;
Data are also emerging on the effects of rehabilita-
tion on respiratory diseases other than COPD.
Important areas for future research concern [13]:
- the length of the programs and strategies to main-
tain the benefits obtained;
- more efficient use of scarce resources;
- individualization of the program to different 
phenotypes of clinical COPD;
- better definition of optimal training schemes;
- the supplementation of oxygen in various situa-
tions of hypoxemia (resting, stress, night);
- the use of non-invasive ventilation;
- nutritional supplementation;
- electrical stimulation of muscles and peripheral
respiratory muscles;
- the role of exacerbation to influence results of
rehabilitation and viceversa.
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The institutions  
Le Istituzioni 
Giovanna Laurendi  
Department of Health Prevention, Ministry of Health, Labour and Welfare, Rome, Italy
The incidence of chronic respiratory disease has
increased steadily over the past several years and
currently constitutes a serious public health prob-
lem. Chronic respiratory diseases are often under-
diagnosed. Many patients are not diagnosed until
the chronic respiratory disease is so severe as to
prevent normal daily activities, including atten-
dance at school or work.
The prevention of chronic disease, particularly of
chronic respiratory diseases, and the reduction of
their social and individual impacts is based on the
modification of environmental and social factors,
and the improvement of diagnosis and treatment.
Today, many risk factors have been identified:
tobacco smoke, allergens, occupational agents,
indoor air pollution and outdoor pollution.
Prevention of these risk factors will have a signifi-
cant impact on morbidity and mortality.
In a country such as Italy, where life expectancy is
continuously rising, it is important to set up respira-
tory disease preventive measures, in order to
achieve better health conditions and preserve the
population’s quality of life.
The Italian Ministry of Health has made respiratory
disease prevention a top priority and has been grad-
ually putting in place a comprehensive strategy. It
has a role in the implementation of policies against
tobacco smoking, indoor and outdoor pollution,
obesity, and communicable diseases. Presently,
these actions are not well integrated, and this poor
coordination is an important limitation for the
Ministry of Health. Therefore, the GARD initiative is
a great opportunity for the Ministry of Health which
may play a role in coordinating GARD in Italy.
Following the WHO-GARD guidelines, we have
collaborated in the creation of the Italian GARD.
The main objective is to discuss the development of
a global chronic respiratory disease program in
Italy. Effective prevention implies setting up a health
policy with the support of health care professionals
and citizen associations at the national, regional,
and district levels. What is required is a true inter-
institutional synergy: prevention of respiratory dis-
eases cannot and should not be the responsibility of
doctors alone, but should involve politicians/policy
makers, as well as the media, local institutions,
school, and food producers. 
GARD could be a significant experience and a great
opportunity for Italy, and a means to implement the
GARD vision of a “world where all people can
breathe freely”.
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0 Role of patients’ associations  
Il ruolo delle Associazioni di pazienti 
Fausta Franchi  
Vice President, Italian Association of COPD Patients, Rome, Italy
The right to health, as defined in the Italian
Republic Constitution, is one of the fundamental
rights of an individual.
The search for different, new equilibria in which it
is the individual, and not the disease, at the centre
of the system, requires a greater responsibility on
the part of all the players involved, including the
patients, to achieve the goal of preventing or delay-
ing the development of complications.
Therefore, interventions must be coordinated among
scientific societies, professional associations, volun-
teer organisations, and public and private institu-
tions. It is thus necessary to develop assistential pro-
files based on a multidisciplinary approach and
ensure continuity among actions of prevention, treat-
ment and rehabilitation, with intersectorial interven-
tions, both medical and social, able to involve also
the family and volunteer organisations.
In the approach to chronic diseases in general, and
to COPD in particular, we must work to empower
the people, i.e. make them able to participate
actively in the therapeutic choices that concern
them and in the decisional processes aimed at
improving their quality of life and reducing compli-
cations. Patients must be helped to obtain “ability”
through acquiring knowledge about the disease and
treatments available. Indeed, knowledge is essential
to obtain a good level of healthcare that places the
patient at its centre. On the other hand, it is also
necessary that the health care system and social
services are aware of people’s needs, and are able
to work together to trigger a process of improve-
ment, that respects the rights and freedom of the
individual.
Primary care  
Medicina di base 
Giovanni Invernizzi
Tobacco Control Unit, Istituto Nazionale dei Tumori/SIMG Italian College GPs, Milan, Italy
Due to its increasing prevalence, COPD is consid-
ered a social disease which warrants special atten-
tion at primary care level. General practitioners
(GPs) have a central role in disease prevention,
detection, treatment, and management. This applies
also to COPD. Smoking cessation intervention is the
cornerstone for preventing COPD: GPs’ attitude
towards offering brief advice to every smoker in the
office is becoming a rule, as well as their awareness
to belong to the wider network of anti-smoking
services. The manifold contacts on a yearly basis
with their patients who smoke allow GPs to carry
out early detection by means of spirometry, and to
collaborate with pneumolgists if needed. COPD
treatment should be based on regular therapy with
inhaled drugs (long-acting bronchodilators and
steroids) to ensure a good quality of life. Prevention
and treatment of exacerbations is of the utmost
importance: avoiding airborn pollutants (environ-
mental tobacco smoke and urban pollution) is
mandatory, while early recognition of an exacerba-
tion, and starting oral steroids and antibiotics courses,
are the cornerstone of good practice by GPs.
Finally, COPD management is based on planning
regular clinical and functional follow up.
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Role of the respiratory specialist  
Il ruolo dello specialista di ambito respiratorio 
Stefano Nardini  
Pulmonary and TB Unit, General Hospital, Vittorio Veneto (TV), Italy
Respiratory diseases constitute an emergency.
Altogether (including lung cancer) they represent
the 2nd major cause of mortality and are likely even
more frequent than we know given the under-diag-
nosis that today exists [1-2]. The future trend is for a
still further increase, although differentiated for the
different diseases [3]. As for other chronic diseases,
we need to re-think the organization of health care
provided for respiratory diseases. Specialists need
ongoing training not only on the “technical” front
but also on health care planning, and must be
informed about management and systemic issues
based on solid epidemiological data or estimates.
Background: respiratory diseases
Cancerous diseases. Lung cancer is everywhere one
of the primary causes of cancer mortality [4]. Life
expectancy at the time of diagnosis is low and has
not substantially modified in the last decades due in
part to the lack of procedures for early diagnosis
[5].
Chronic obstructive diseases. These diseases (in par-
ticular, COPD and asthma) rank amongst the fore-
most causes of death and invalidity. COPD is very
widespread, affecting at least 10-15% of the adult
population [6]. It is estimated that COPD will rank
3rd as a cause of morbidity and 6th as a cause of mor-
tality in 2020 [7]. The prevalence of asthma shows
a wide variation among the different countries,
ranging from 2-4% in the large Asian countries to
15%-20% in England, Canada, Australia and New
Zealand [8]. In Italy, its prevalence is about 7% in
children [9]. Asthma is moreover the most frequent
occupational disease.
Infective respiratory diseases. In contrast to other
specialist disciplines like gastroenterology, last cen-
tury did not see a reduction in the morbidity due to
infective respiratory diseases (pneumonia and
tuberculosis being the most important). Today, the
incidence of pneumonia ranges from 4.7 per 1000
inhabitants/year in the U.K. general population to
14 cases in the more elderly populations in Spain
[10-11]; some countries have recently witnessed a
rise in hospitalizations [12]. Tuberculosis is, after
HIV infection, the 2nd most frequent cause of death
from infective disease in the world [13].
Obstructive apneas. Obstructive sleep apnea syn-
drome (OSAS) is very widespread. The estimated
prevalence in Italy is 2.7% of the adult population,
though among males aged > 40 years it is 12% and
for professional drivers it is 17% [14]. One of its
consequences is daytime sleepiness that can cause
accidents, in particular driving accidents (22% of
which are due to eccessive sleepiness). 
Cigarette smoking. The two most important respira-
tory diseases (lung cancer and COPD) are in the
overwhelming majority of cases caused by cigarette
smoking, which also worsens the disease course.
Smoking is both a risk factor and a disease in itself.
With variations between the different countries,
smoking affects on average ¼ to 1/5 of the popula-
tion [15]. The specialist is involved in both its pre-
vention and treatment.
Economic and social costs of respiratory diseases
The total cost of respiratory diseases in Europe is
more than €100 billion per year. COPD contributes
to at least half of this figure, followed by asthma,
pneumonia, lung cancer and tuberculosis. In gener-
al, inpatient hospital services represent 17.5% of
the total cost, outpatient care 8.9%, pharmaceutical
drugs 6.6%, mortality and rehabilitation 19.6%,
and lost work days 47.4% [16].
The annual cost for medical treatment alone (direct
healthcare costs) for a patient affected by COPD has
been calculated in France to exceed €4,300,
almost half of which is related to hospital admis-
sions and one third to pharmaceutical drugs. The
overall cost of COPD for France (based on a preva-
lence of 1.3%, and hence only very approximate,
see below) has been estimated at €3.5 billion, i.e.
3.5% of the total medical expenditure [17]. Also the
cost for the employer is elevated [17-19]. The social
impact of COPD is very high, particularly in the
phase of respiratory failure when the social life of
the patient, now invalid, is reduced to zero.
The direct costs of asthma constitute 1-2% of over-
all healthcare costs in Italy. Indirect costs (concern-
ing work and family) represent 60% of the overall
costs. The cost/year of an adult asthmatic (aged 20-
45 years) is estimated at €800 (with an incidence
on family income between 2 and 8%). 11% of adult
asthmatics and 19% of child asthmatics will be hos-
pitalized at least once for asthma, and 19% and
31%, respectively, will require an emergency visit.
Asthma in children is responsible for absence from
school (31% of total school absences are related to
asthma) and absence from work for the family.
Trends in respiratory disease
Besides active smoking as the cause of the principal
respiratory diseases, these latter are also linked to
indoor and outdoor pollution (in the home, public






























0 next few years are for:
- a rise in COPD (due to the increase of the average
age and a decline in underdiagnosis), asthma
(due to reasons not yet fully clear), and OSAS
(due to an increase in the average body weight
and a decline in underdiagnosis). 
- stable trend for smoking (with country to country
variations), lung cancer (in decline amongst
males but on the rise amongst females), tubercu-
losis (dependent on the migratory flows), and
pneumonia. 
Role of the specialist in healthcare planning
To deal with chronic respiratory diseases and opti-
mize their management, there is need for a global
approach that can define, on the basis of solid epi-
demiological data, the best care for the patient
throughout the course of the disease, in a way that
is sustainable for the community. 
Numerous initiatives and studies are under way
everywhere. One of these, which for reasons of
space we will focus on here, is the Global Alliance
against chronic Respiratory Diseases (GARD), an
ensemble of national and international organiza-
tions guided and coordinated by the World Health
Organization (WHO): GARD’s strategies and corre-
sponding actions [20] delineate the role of the spe-
cialist at global and national level. For example, in
Italy, the Ministry of Health – which defined chronic
respiratory diseases as a priority of the national
Health Program 2006-2008 and hence finalized,
with the National Agency for Regional Healthcare
Services (AGE.NA.S) the national guidelines for
COPD – launched in 2009 GARD-Italy. [21].
Respiratory specialists participate in the “central”
planning phase of all these initiatives, while other
specialists participate in the “peripheral” phase of
implementation. Successively, these same special-
ists verify the applicability in the real world and the
final efficacy of what has been planned and imple-
mented. Following we will see how.
Role of the specialist in implementing healthcare
strategies 
Today patients affected by chronic pulmonary dis-
eases are managed in a discontinuous and non inte-
grated mode with inappropriate care procedures as
a consequence. In turn, the prevention of these dis-
eases is neither systematized nor integrated. 
Inappropriateness costs both the individual and the
community. It has been calculated that GBP £1.3
billion are spent each year in the U.K. for
Emergency Care visits for patients with 18 diseases
(and 3-4 visits per individual patient). Occupying
first place in the list of diseases is COPD and in
third place is asthma. Varying percentages of these
visits resulted inappropriate at a retrospective
analysis [22]. An optimal management of the above
diseases would not only reduce the crowding of
Emergency Care facilities and the global healthcare
costs, but would also improve the conditions of life
of those affected. 
The long term goal must be to reduce the incidence
of respiratory diseases while the short- and medi-
um-term goal is to reduce - in an economically sus-
tainable way – the social and economic conse-
quences of the diseases already present, through a
greater appropriateness. 
The specialist thus has a role to play in primary pre-
vention, early diagnosis and rehabilitation, as guide
or coordinator or consultant depending on the type
of intervention. The interventions to promote are
[23]:
1.to prevent respiratory disease developing through
a consistent reduction of the number of smokers
in the community and total control of risk factors;
2.to improve and anticipate diagnosis, in particular
of COPD and asthma, through a more wide-
spread use of spirometric tests and specialist
expertise;
3.to help patients self manage their own disease,
through health education and pulmonary rehabil-
itation;
4.to integrate the care of patients affected by respi-
ratory diseases, through linking specialist care to
primary care, and extending end of life treatment
from the oncological to the respiratory sphere.
In concrete terms, the specialist will build up a net-
work in which the Operational Unit functions as the
junction for the whole “vine” of respiratory care
that begins with primary prevention and goes right
through to palliative care, e.g. according to the fol-
lowing scheme of action: 
- in primary prevention:
- implement smoking cessation in prevention
and treatment
- increase the opportunity for screening for
obstructive sleep apnea
- in secondary prevention:
- increase accessibility to lung function 
assessment
- experiment screening models for lung cancer
- in improvement of patient management:
- expand and rationalize semi-intensive treatment
- further reduce hospitalization through integration
with services available in the local community, e.g. 
home hospitalization 




- experiment a model of pulmonary rehabilitation
provided in the local community
- experiment the extension of palliative care to
patients with severe respiratory failure.
Conclusions
Healthcare planning for respiratory diseases must
undertake a whole re-think of its “mission” and a
reorganization of the specialist network based on a
redefinition of the role of the specialist. The goal is
to achieve greater possibilities of self-management
for the patient, greater responsibilization of primary
care givers, through use of telemedicine, optimal
crisis management, and greater options for dedicat-


























pital pulmonary unit is similar to that of modern
cardiology (i.e. intensive management of the acute
crisis and of the immediate post-acute period in
hospital) while that for the local community is akin
to that of the services of diabetology (i.e. specialist
consultation and guidance) with particular focus on
self-management and pulmonary rehabilitation for
patients with respiratory failure. The hospital spe-
cialist, who needs to be part of a Specialist Unit in
order to have full knowledge of all the aspects, main-
tains the direct management of emergencies. For this
the Pulmonology Unit must be an integral part of the
critical area and not of the medical area, and its role
in activities of non invasive respiratory intensive care
needs to be recognized and promoted.
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Long term oxygen therapy: a critical re-evaluation of current
guidelines  
Ossigenoterapia a lungo termine: una rivalutazione critica delle linee guida attuali 
Antonio Corrado, Teresa Renda
Respiratory Intensive Care Unit, Careggi Hospital, Florence, Italy
Oxygen therapy represents an essential part of treat-
ment in the care of COPD patients with chronic res-
piratory failure. The evidence supporting the large
use of oxygen therapy and the current indications of
international documents are based on the two land-






























0 NOTT and MRC - published more than 25 years
ago [1,2]. These studies showed that stable COPD
patients, recruited according to pre-established
inclusion criteria, live longer when they receive
domiciliary long term oxygen therapy (LTOT) for
more than 15 hours/day. The effectiveness of LTOT
in improving survival has been documented only in
COPD patients with severe chronic hypoxemia
(PaO2 less than 55 mm Hg (7.3 kPa) or PaO2 ranging
from 56 to 59 mmHg (7.4-7.8 kPa) in the presence
of signs of cor pulmonale, hematocrit > 55%). The
LTOT indications (based on NOTT and MRC) were
established in a very selected and limited number of
patients that are unlikely to represent the hetero-
geneity of the COPD population. These recommen-
dations have been subsequently extended, albeit
without solid evidence, to COPD patients with
moderate hypoxemia (55 < PaO2 < 65 mmHg), and
to patients with decreased oxygen saturation (SaO2
< 90%) during exercise or sleep [3-7]. Increased life
expectancy in the general population will lead into
an increase in the numbers of patients surviving
beyond age 70 with chronic diseases, like COPD.
Comorbidities are very likely to affect both progno-
sis and health outcomes in COPD patients but clin-
ical practice guidelines do not provide adequate
guidance for patients in LTOT with complex chronic
diseases. 
It has been reported that reassessment of the indica-
tion for LTOT after some months of clinical stability
reduced significantly the number of patients who
would be eligible for LTOT soon after an episode of
exacerbation [6]. The stability of underlying chronic
disease before commencing LTOT is crucial.
Actually, many COPD patients are prescribed oxy-
gen therapy because they are hypoxemic at dis-
charge from hospital after exacerbation of an under-
lying respiratory disease, despite an absence of data
to support short- or long-term benefits of oxygen
therapy. After acute exacerbations of COPD approx-
imately 30-38% of patients improved PaO2 values
merely by optimizing medical management to the
extent that they no longer fulfilled the selection cri-
teria for LTOT [8]. In order to optimize oxygen use
it is advisable that patients should be reassessed,
both at 3 months and at approximately one year
after commencing oxygen therapy [9]. 
Furthermore, it is generally accepted without evi-
dence that LTOT in clinical practice is warranted in
other forms of chronic respiratory failure such as
pulmonary fibrosis, kyphoscoliosis, and cystic fibro-
sis when arterial blood gas criteria are similar to
those established for COPD patients. Given the
increasing numbers of patients receiving supple-
mental oxygen as treatment and the high costs
incurred in providing oxygen therapy, a critical revi-
sion of the actual indications for LTOT is needed,
particularly for COPD patients with comorbidities,
mild-moderate hypoxemia, and exercise and sleep
desaturation. Nevertheless, the high overall cost of
LTOT is an argument in favour of prescribing it only
for patients in whom there is a reasonable expecta-
tion of clinical benefit. 
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Lessons from large international clinical trials  
Le lezioni dei trial clinici internazionali 
Antonio Anzueto
Pulmonary Medicine and Critical Care, University of Texas Health Science Center and South Texas Veterans Health
Care System, San Antonio, Texas, USA
COPD is a major cause of morbidity and mortality
worldwide. Airflow obstruction is variable and
results in hyperinflation, the hallmark of COPD
physiological impairment. Besides the decline in
lung function, COPD patients experience signifi-
cant limitation in their daily life including dyspnea,
exercise capacity, frequent exacerbations and hos-
pitalizations. Long acting bronchodilators including
β-agonists and anticholinergics with or without
inhaled corticosteroids have been shown to impact
these factors. Published studies over the last several
years of pharmacotherapy have demonstrated
improvements in lung function, dyspnea, decreases
in exacerbations, improvements in health-related
quality of life (HRQoL), and decreased mortality.
Bronchodilators have also been associated with a
reduction of dynamic hyperinflation, increased
inspiratory capacity (by reducing the functional
residual capacity), decreased work of breathing,
improved ventilatory capacity and less dyspnea dur-
ing activity and formal exercise testing. The long-
term efficacy and safety of these medications were
demonstrated in several multi-center, double-blind,
1-4 year long clinical trials.
Tiotropium, the first medication in the new class of
long acting anticholinergics, exhibits a longer dura-
tion of action and has more specific muscarinic
receptor antagonism. Its mode of action allows the
medication to be given once a day, and further stud-
ies have shown that its half-life can be up to 36
hours. Clinical studies of long-acting bronchodila-
tors, long-acting β-agonists (formoterol, salmeterol
and recently indacaterol) and long-acting anti-mus-
carinic agents (tiotropium) showed significant
improvement in trough, peak FEV1 (range, 0.1-0.3 L)
and average FEV1 (range, 0.1-0.25 L) compared to a
decline in placebo-treated patients (short-acting 
β-agonists, salmeterol and/or ipratropium).
Comparable results were achieved with FVC meas-
urements. In order to compare the efficacy between
these long-acting bronchodilators, Donohue et al.
conducted a 6-month, placebo controlled, parallel
group study of tiotropium vs. salmeterol in patients
with COPD. Both active treatments resulted in sig-
nificant improvement in trough, average (0 to 12
hours), and peak FEV1 compared with placebo 
(p < 0.001). At the end of 24 weeks however,
trough, average, and peak FEV1 improved signifi-
cantly more with respect to placebo in the tiotropi-
um group than in the salmeterol.
Clinical studies evaluated the use of combination of
tiotropium and long acting β2 agonists showing that
there is a synergistic effect of the combination ther-
apy and further improvement in lung function. This
combination therapy will be suitable for patients
with severe disease. The sustained improvement in
lung function seen in these studies suggests that
long active bronchodilators may slow the decrease
in lung function over time and subsequently change
the clinical course of the disease.
Furthermore, the impact of combination therapy
(fluticasone propionate/salmeterol, and for-
moterol/budesonide) on patients’ mortality, fre-
quency of exacerbations and long-term effects on
lung function has been reported. The TORCH
(Towards a Revolution in COPD Health) trial is a
large study that prospectively investigated the
potential for combination therapy (fluticasone pro-
pionate/salmeterol) to impact survival in patients
with COPD. TORCH was a three year, multicenter,
randomized, double-blind, parallel group, placebo
controlled study. Approximately 6,112 patients
were randomized into 4 study groups: placebo, sal-
meterol, fluticasone propionate (500 µg), and fluti-
casone propionate/salmeterol (500/50 µg). The pri-
mary end point was the reduction in all-cause mor-
tality, comparing fluticasone propionate/salmeterol
with placebo. Secondary end points included
COPD morbidity (rate of exacerbations) and quality
of life assessment. The study showed a 17% relative
reduction in mortality over three years for patients
receiving fluticasone propionate/salmeterol as com-
pared with placebo (p = 0.052); a 25% reduction in
exacerbations compared with placebo; and signifi-
cant improvement in quality of life measured by the
St. George’s Respiratory Questionnaire (SGRQ).
Taken together, existing data suggest that a fixed
combination of long-acting β-agonists (LABA)/
inhaled corticosteroid therapy has a significant
impact in COPD by improving lung function, symp-
toms and HRQoL, as well as reducing exacerba-
tions. Importantly, this therapy may also alter the
course of the disease by
reducing mortality.
The UPLIFT study results were recently reported.
UPLIFT was a randomized, double-blind, placebo-
controlled, parallel group trial designed to assess
range of clinical parameters, including the rate of
decline of lung function, quality of life, exacerba-
tion frequency, rate of hospitalization and mortality
in COPD patients (GOLD Stages II, III and IV) treat-
ed for 4 years with tiotropium 18 mcg inhalation
capsule once daily. The study was conducted at 600
centers and involved over 6,000 patients. Findings
showed that tiotropium compared with standard






























0 dilator effect, less dyspnea, superior health scores,
and fewer COPD exacerbations and hospitaliza-
tions. Tiotropium was also shown to be safe with
significant less cardiac related events. Except for dry
mouth incidence in tiotropium, adverse events were
comparable with placebo. These data suggest that
tiotropium has a significant role in COPD therapy.
Clinical studies using triple therapy - tiotropium and
fixed combination of long-acting bronchodilator
and inhaled corticosteroid – have demonstrated an
enhanced improvement in lung function, and
reduction of exacerbations as compared with any
product alone. Several of these studies also showed
improvements in morning and daytime symptoms,
nighttime awakenings, reliever use, and HRQoL. In
COPD patients with severe and very severe disease
triple therapy is highly effective.
Regardless of whether the treatment paradigm is
driven by symptoms or spirometry, an important
issue is whether regular treatment with long-acting
bronchodilators and/or the combination of LABA-
inhaled corticosteroids should be initiated at earlier
stages of the disease. Recent reports of a sub-analysis
of TORCH and UPLIFT studies show that patients
with moderate disease will benefit from these ther-
apies. These studies showed significant increase in
trough FEV1, peak FEV1, dyspnea score, and HRQoL
measured by the SGRQ. Notably, patients also have
a significant reduction in exacerbations.
Roflumilast, an investigational selective phospho -
diesterase 4 inhibitor, taken orally once daily targets
the inflammation that is a hallmark of the disease.
Participants in several 6- and 12-month studies who
received roflumilast alone or in combination with
salmeterol and/or tiotropium had a significant
improvement in lung function, quality of life and
reduction in exacerbations. Adverse events were
mostly mild in nature. The two most frequent in the
roflumilast group were diarrhea and weight loss.
This medication is awaiting approval by the regula-
tory agencies.
In COPD patients, both airflow limitation and
deconditioning lead to reduced exercise tolerance.
Pulmonary rehabilitation (PR) has been shown to
improve exercise tolerance, as well as dyspnea. A
placebo-controlled trial tested the hypothesis that
improvements in ventilatory mechanics resulting
from tiotropium use would permit enhanced ability
to train muscles of ambulation and, therefore, aug-
ment exercise tolerance benefits of PR. Tiotropium
in combination with PR improved endurance in a
constant work rate treadmill task and produced
clinically meaningful improvements in dyspnea and
health status compared with PR alone. Furthermore,
following PR completion, improvements with
tiotropium were sustained for 3 months. These data
demonstrate that using long-acting bronchodilators
will enhance the benefits of PR.
In conclusion, as the incidence of COPD increases,
the need for agents that reduce associated morbidity
and mortality is ever-growing. Long-acting broncho -
dilators alone and in combination with inhaled cor-
ticosteroids signify a major advancement in the
management of COPD. These medications have
been shown to improve lung function, quality of life
and exercise performance, decrease exacerbations,
and reduce hospitalizations. Recent long term stud-
ies (3 to 4 years) showed sustained improvement in
lung function, decreased mortality, and safety of
these medications.
Several new long-acting bronchodilators are under
investigation in clinical trials and will become
available in the years to come.
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The situation in North America: view from Canada   
La situazione in Canada 
Rick Hodder   
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The BOLD survey [1] estimated the prevalence of
COPD in persons aged 40 years or older in Canada
to be 11.1% (Stage I), 7.3% (Stage II) and 0.9%
(Stage III-IV) or about 3.3 million. This is consider-
ably higher than the official estimate of 750,000
Canadians with COPD that is based on reported
physician diagnosis [2]. Clearly, as in other coun-
tries, there is a very large undiagnosed COPD pop-
ulation in Canada [3]. Despite this, respiratory dis-
eases rank fourth in Canada in terms of the propor-
tion of healthcare costs [2]. Hidden COPD in
Canada is like a tsunami gaining strength, but
which has yet to wreck on the shores of Canada’s
healthcare system, a system largely unprepared for
the huge stresses that threaten to overwhelm our
infrastructure, healthcare personnel, and financial
resources. This in turn will prevent us from provid-
ing the comprehensive health care that these
patients will need.
Healthcare in Canada is funded by each of our 10
provinces and 3 territories, with some additional
federal funding transfers. Approximately 70% of
total healthcare expenditure is financed by govern-
ment (provincial, territorial, federal) taxation [4]. All
hospitalizations, physician visits and home care
services are covered by the public purse. Patients do
not have to pay for their assessments and there are
no co-payment requirements, which allows
Canadians to access a physician more easily than in
many other countries. Primary care providers (PCP)
are usually the first point of care for patients with
COPD and the majority of physicians (PCPs and
specialists) are paid on a fee-for-service basis
according to the provincial fee schedule.
Consultation by specialists, including ‘respirolo-
gists’ is generally arranged through a PCP, because
services for non-referred patients are paid at a lower
rate. The cost of delivering COPD care in Canada
has been assessed [5-8]. The Canadian RUSIC study
[5] estimated that acute exacerbations of COPD
(AECOPD) requiring a medication change plus a
visit to an outpatient facility including an emer-
gency department had a mean cost of $641 (CAN
2006 $), whereas the mean cost of an AECOPD































0 requiring hospitalization was $9,557. In 2003, data
from the Confronting COPD Survey were used to
estimate that the annual direct cost of COPD care
including laboratory tests and visits to PCPs and
specialists, was almost $2000 per patient, with
about half of the costs due to hospitalization [7].
The estimated economic burden of COPD through
work loss was $1,198 per patient, giving an annual
societal cost of $3,195 per patient. Costs increased
in direct proportion to the severity of COPD as
measured either by FEV1 or MRC dyspnea score.
Clearly, any therapy that will reduce the frequency
of AECOPD, improve symptoms and slow down the
age-related loss of FEV1 in COPD should reduce
associated healthcare costs over time.
There is no universal drug plan in Canada, and pri-
vate payments are required for many citizens for
medications, medical devices, some investigations
and alternative practitioners such as chiropractors
and optometrists. These payments are split between
out-of-pocket expenses (15%), and private health
insurance (12%), with the remaining 3% of pay-
ments provided by social services, charities and
workmen’s compensation benefits [4]. Provinces
pay for medications for senior citizens (age 65 and
over) and those on social services, but the medica-
tions provided come from a restricted list, which
varies from province to province. This can be prob-
lematic in that the provincial drug formularies often
favour generic versions of low cost drugs [9]. Thus
while the Canadian [3] and other [10] clinical prac-
tice guidelines (CPG) for COPD recommend a long-
acting anticholinergic bronchodilator or a LABA as
first line treatment and combinations of long-acting
bronchodilators (LABD) with or without inhaled
corticosteroids (ICS) for more advanced disease,
these restrictive provincial formularies act as barri-
ers to physicians who wish to follow the CPGs.
For example, only 3 of 10 provinces fully funded
tiotropium for COPD, while the remainder placed
restrictions on its use, such as requiring that the
physician provide spirometric documentation of
advanced airflow obstruction and evidence of treat-
ment failure on high dose ipratropium, before grant-
ing funding for the long-acting anticholinergic
agent [9]. Similar restrictions exist for the combina-
tion LABA/ICS inhalers for COPD. A recent survey
of Canadian PCP practice patterns in COPD in the
provinces of Ontario and Quebec (CAGE study)
observed that pharmacologic treatment that
matched Canadian CPGs was present in only 34%
of practices [11]. Non-prescription of LABDs for
patients with moderate and severe COPD occurred
in 27% and 21% of cases respectively and prescrip-
tion of two LABDs for advanced COPD occurred
only 49% of the time. A recent attempt [12] has
been made to perform a cost effectiveness analysis
of the Canadian [3] and GOLD [10] CPG COPD
pharmacotherapy recommendations based on the
results from the Canadian OPTIMAL trial [13]. This
trial demonstrated that triple therapy with tiotropium
plus fluticasone plus salmeterol (TFS) was superior to
tiotropium plus salmeterol (TS), or to tiotropium
alone with respect to lung function, frequency of
AECOPD requiring hospitalization and quality of
life. The cost effectiveness analysis demonstrated
that the incremental cost per exacerbation avoided
with TFS was $6,510 (CAN) and the incremental
cost per quality adjusted life year (QUALY) gained
was $243,180 (CAN) [12]. Put in the context of
what is considered an acceptable (to society) cost
per QUALY gained and per AECOPD avoided, the
authors of this analysis concluded that neither TFS
nor TS were economically attractive alternatives
compared with monotherapy with tiotropium for
moderate-to-severe COPD [12]. 
It remains to be seen whether governments and
third party payers will begin to consider requiring
this type of cost effectiveness analysis when con-
structing lists of which drugs to support financially.
Also yet to be considered is the price to society of
increased longevity in COPD, such as that suggest-
ed recently in response to sustained bronchodilator
therapy with expensive long-acting bronchodila-
tors, with or without ICS [14-16]. 
Non-pharmacologic COPD therapies such as pul-
monary rehabilitation (PR) have also undergone
cost/benefit analysis in the Canadian context [6].
An economic analysis of a 2-month inpatient fol-
lowed by 4-month outpatient PR program in
Canada in 1997 estimated that it cost $11,597
(CAN) to achieve clinically significant gains in dys-
pnea, emotional function, and mastery, with more
than 90% of the costs being due to the inpatient
phase of the program [6]. This data ignores potential
cost savings resulting from fewer hospitalizations
for COPD patients successfully completing a PR
program [17]. It also emphasizes the value and
potential cost-effectiveness of developing smaller
outpatient and home-based PR programs [18].
A recent review has suggested that the most signifi-
cant gains in COPD healthcare utilization have
been realized by collaborative self-management
education (SME) interventions [19]. A Canadian
randomized controlled trial comparing case man-
ager-driven SME versus usual care demonstrated a
40% reduction in the need for COPD patients to
access healthcare resources including hospitaliza-
tions, emergency department visits and unsched-
uled clinic visits [20]. A cost-effectiveness analysis of
this trial demonstrated significant net savings of
$2,148 (CAN) per patient, provided the case manager
supervised 50 or more patients per year [8]. Canada
is the first country to have certified respiratory educa-
tors (CRE), although many of these individuals are not
fully employed. This reflects an under appreciation of
the benefits of a collaborative self-management edu-
cation approach to COPD care, which has led to
under funding for such individuals. However, the sit-
uation is beginning to change as many provinces are
moving towards a restructuring of primary care into
multidisciplinary teams which are given financial
incentives to provide comprehensive care including
CRE-facilitated SME and whose physicians often for-
feit fee-for-service remuneration in return for a salary
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The situation in North America: view from the United States  
La situazione negli USA 
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COPD is a highly prevalent and morbid condition
affecting 20-24 million United States citizens.
COPD is the fourth leading cause of death in the
U.S. with more than 125,000 deaths annually. In
2010, the direct health care costs of COPD are pro-
jected to total $29.5 billion [1]. Of these costs,
$13.2 billion are hospital care costs, $5.5 billion
are physician costs, $5.8 billion are outpatient pre-
scription drug costs, $1.3 billion are home health






























0 Moreover, long-term oxygen therapy costs
Medicare more than $2 billion per year for COPD
and the cost is growing by 12-18% per year [2]. In
addition, there are $20.4 billion in indirect costs
due to lost productivity from death and disability.
Lung volume reduction surgery and lung transplan-
tation, although costly procedures, are infrequently
used in COPD, so they do not presently account for
substantial healthcare costs [3]. The primary goals
of treating COPD are to improve functional status,
reduce morbidity, and prolong survival. However,
because substantial costs of COPD are related to
health care use for exacerbations, it is a reasonable
goal to consider therapy in terms of reduction in
health care costs as well as direct expense for the
drugs. 
The current status of pharmacoeconomic evalua-
tions of COPD has recently been critically reviewed
and, while a number of methodologic flaws were
found, the results were generally concordant [4].
Three older retrospective analyses have shown that
the anticholinergic bronchodilator ipratropium in
early stage COPD and a combination anticholiner-
gic-β-agonist in more advanced COPD are associat-
ed with lower overall healthcare costs, largely
because of reduction in exacerbations requiring
hospital care [5]. Another retrospective analysis
compared costs of COPD treatment with ipratropi-
um vs. theophylline [6]. Although the direct drug
costs for ipratropium were greater, the overall
healthcare costs were 28% lower in those patients
treated with ipratropium, mainly because of reduc-
tion in exacerbations. An analysis of healthcare
costs from a health maintenance organization data-
base showed that monotherapy with ipratropium
was associated with a reduction in healthcare costs
compared to monotherapy with either a β-agonist,
inhaled steroid, or theophylline in the first six
months following a COPD diagnosis. Subsequent
treatment with combination therapy with ipratropi-
um and a β-agonist were also lower than other ther-
apy groups [7]. These observational studies were
supported by an economic analysis of two clinical
trials of ipratropium-albuterol combination com-
pared to ipratropium or albuterol alone [8]. Both of
the ipratropium arms of the study indicated lower
direct healthcare costs than albuterol alone. Again,
the main component of the reduced expenditures
was related to fewer exacerbations and fewer hos-
pitalizations. 
Long-acting β-agonists (LABA) as monotherapy for
COPD are effective in reducing exacerbations com-
pared to placebo, and a review of two clinical trials
indicates that this translates into a reduction in
healthcare expenditures, although these studies did
not provide a comparison to other bronchodilator
monotherapies [9]. Monotherapy with an inhaled
corticosteroid, fluticasone, assessed in a placebo-
controlled trial was found to be associated with a
reduction in both direct healthcare expenditures as
well as indirect healthcare costs from days of inca-
pacitation [10]. A clinical trial comparing the long-
acting anticholinergic tiotropium to ipratropium
demonstrated a 26% reduction in exacerbations
and 46% reduction in hospitalizations associated
with tiotropium. Calculations of costs using stan-
dard costs in The Netherlands indicated that the use
of tiotropium, although more effective, was associ-
ated with increased healthcare costs for tiotropium
due to the increased cost of drug acquisition. The
cost-effectiveness of tiotropium vs. ipratropium is
sensitive, however, to the relative costs of drug-
acquisition compared to hospitalization and may
have demonstrated a different effect on healthcare
costs in the United States where the costs and
charges for hospitalization are substantially higher
than in The Netherlands [11]. This is further support-
ed by a Spanish modeling study using outcome data
from clinical trials comparing cost-effectiveness of
monotherapy with salmeterol, ipratropium, and
tiotropium. All three treatments were cost-effective
in terms of clinical outcomes, but the most effective
and highest cost monotherapy treatment was
tiotropium [12]. Different strategies for initiation of
inhaled corticosteroid therapy (ICS) in COPD were
analyzed using a Markov chain model and using
the assumption that ICS cause an initial increment
in lung function but no change in the rate of subse-
quent decline. This analysis, which is highly
dependent upon the assumptions regarding fre-
quency of exacerbations and transition between dif-
ferent stages of COPD, suggested that the cost-
effectiveness of ICS was greater in the most severely
impaired individuals [13]. 
Three economic analyses of the TORCH trial have
been published. TORCH compared salmeterol-fluti-
casone combinations (SFC) to the individual com-
ponents and placebo. In one study using the United
States cost structure, salmeterol was the most cost-
effective drug ($20,792/QALY) and SFC was second
most cost-effective ($33,865/QALY). Fluticasone
alone, which did not improve survival in TORCH
was not considered cost-effective [14]. A similar
Markov-chain analysis of the TORCH trial, using
different cost assumptions, found that SFC was the
most cost-effective ($52,046/QALY), followed by
salmeterol monotherapy ($56,519/QALY) and fluti-
casone monotherapy ($56,519) [15]. In a third
analysis of TORCH, using a multinational approach
to cost structure, SFC was also found to be most
cost effective with a cost of $43,600 per QALY,
compared to $197,00 for salmeterol monotherapy
and $78,000 per QALY for fluticasone monothera-
py. The cost-effectiveness was considerably lower
for SFC in the United States ($77,100/QALY) com-
pared to Western Europe ($24,200/QALY) [16].
Analysis of a Medicare HMO database using actual
healthcare expenditures compared the costs of ini-
tial maintenance therapy for COPD using FSC, ipra-
tropium monotherapy, ipratropium-albuterol
monotherapy, and tiotropium. In this retrospective
comparison, SFC was associated with slightly more
cost savings than tiotropium ($110/year), and iprat-
ropium-albuterol ($295/year), but substantially bet-
ter than ipratropium alone ($1235/year) [17]. 


























studies for COPD demonstrates that the analytic
approach and baseline assumptions can lead to
substantial differences in the conclusions that are
reached. Nonetheless, there does appear to be sub-
stantial evidence that maintenance therapy in
COPD is cost-effective and is comparable to the
cost-effectiveness of treatments for other chronic
diseases. 
But the most effective therapies may exceed the
threshold of willingness to pay by third-parties com-
pared to management approaches in other chronic
diseases. There are still substantial gaps in our
knowledge of the comparative cost-effectiveness of
other therapeutic strategies for COPD, particularly
the combinations of therapies from different classes.
In addition, we need to know better how the sever-
ity of COPD and clinical expression of the disease
might influence the cost-effectiveness of compara-
tive treatments. 
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Obstructive lung diseases, particularly COPD are
one of the main causes of morbidity and mortality
in developed countries. In Spain, the prevalence of
COPD was 9% in adults between 40 and 70 years
of age in 1999, although only 22% are diagnosed.
In another population-based study performed ten
years later, the observed prevalence was 10.2% and































individuals with COPD having a previous diagnosis
of the disease.
Considering its high prevalence and the chronic
and progressive course of COPD, it is easy to under-
stand that this disease will represent a high societal
and economic burden. Studies performed in differ-
ent European and American countries have tried to
estimate the healthcare costs associated with the
management of COPD patients. Costs obtained
may differ in numbers, but in all cases they repre-
sent a significant proportion of the healthcare costs
in each country. 
Studies of costs of COPD have been performed in
different countries and differ in their approach and
methodology. In order to compare results among
studies it is important to verify how the study has
been designed. Basically, the differences derive
from the inclusion or not of indirect costs. These
refer to the morbidity and mortality caused by the
disease. They measure the impact which the disease
studied may have on national production. The most
common method of calculation is based on human
capital in which days off work, whether because of
disease or death, are transformed into monetary
units by the application of the mean returns. This
method has been extensively criticized, one of the
reasons being that it does not include the impact on
the collectives which are not integrated in the labor
market such as children, the elderly, housewives,
etc. In contrast, the direct costs are those related to
the detection, treatment, prevention and rehabilita-
tion of the disease studied. Most studies of this type
concentrate on the analysis of the costs incurred by
the hospital, ambulatory and pharmacologic care
related to the disease in question. Other direct costs
apart from health care, such as social services, are
usually not included due to the lack of information.
Another source of variation is the type of analysis.
TABLE I. COMPARISON OF THE COSTS PUBLISHED FOR COPD IN DIFFERENT COUNTRIES IN EUROPE  
Reference Country Focus Costs Cost/patient/year Global cost /year
Morera, 1992 [4] Spain Top-down Direct and indirect €959 Direct €319 M 
Indirect €541 M 
Jacobson, 2000 [9] Sweden Top-down Direct and indirect Direct €109 M 
Indirect €541 M 
Rutten van Mölken, 2000 [6] Netherlands Top-down Direct $876
Dal Negro, 2001 [10] Italy Bottom-up Direct Stage I = €151 
Stage II = €3,001 
Stage III = €3,912 
Jansson, 2002 [11] Sweden Bottom-up Direct and indirect $1,284 $871 M
Miravitlles, 2003 [5] Spain Bottom-up Direct Stage I = €1,185 €427 M 
Stage II = €1,640 
Stage III = €2,333 
Masa, 2004 [12] Spain Bottom-up Direct €909.5 €238.8 M 
Cross-sectional
Izquierdo, 2004 [13] Spain Bottom-up Direct Stage I = €1,657 
Stage II = €2,425 
Stage III = €3,303 
Borg, 2004 [14] Sweden Top-down Direct and indirect Direct costs
GOLD I = €92 
GOLD IIA = €631
GOLD IIB = €2,144
GOLD III = €8,678 
Detournay, 2004 [15] France Bottom-up Direct and indirect Direct costs €3,500 M 
GOLD II = €1,904 
GOLD III = €2,683 
GOLD IV = €6,357 
Lucioni, 2005 [16] Italy Bottom-up Direct and indirect Direct costs
€4,645 
Koleva, 2007 [17] Italy Bottom-up Direct costs GOLD I = €1,046 
GOLD II = €2,319 
GOLD III = €3,572 
GOLD IV = €5,033 
Dal Negro, 2008 [18] Italy Bottom-up Direct costs Mild = €1,314 
Moderate-severe=
€5,451  
De Miguel, 2008 [19] Spain Bottom-up Direct costs €1,922 


























One option would be to calculate the cost of dis-
ease starting with total figures at a national level for
all the diseases together and, thereafter, reach the
level at which the disease studied lies through a dis-
aggregation process: this is called a top-down
analysis. The second option would be to start by
taking a group of subjects with the disease analyzed
together as a base for the calculation and study the
consumption of resources used during the time
period considered. The national total may be deter-
mined by extrapolation of the costs of this subset of
the population: this is called a bottom-up analysis. 
An example of the variation that can be observed in
the calculation of costs is provided by the analysis
of different studies in the same country, as in Spain.
Top-down estimates have been carried out on the
costs generated by COPD in Spain using statistical
and epidemiological data. These studies have
reported figures of around €800 million annually in
1994 including both direct and indirect costs. In a
microeconomic study performed in 1,510 patients
with ambulatory COPD followed over one year
(bottom-up), the average annual cost per patient
was $1,876.00. With this study the approximate
direct annual cost generated by COPD in Spain
may be calculated from the focus of prevalence. If
we take into account data obtained in the IBERPOC
population-based epidemiological study, the preva-
lence of COPD was estimated to be 9% in the 40-
69 year age group, of which only 22% were diag-
nosed and received treatment of some kind.
Therefore, a total of 270,000 subjects would be
diagnosed and treated for COPD multiplied by the
annual average obtaining a total of $506.52 million
annually in direct health care costs generated by
COPD. This figure is greater than that obtained with
the previous focus which may be due to method-
ological differences and also, in part, to differences
in the management of the disease during the period
from 1994 to 1999 when information for the last
study was collected. It is interesting to compare the
distribution of the costs estimated in both models.
In the top-down calculation the hospital costs con-
stituted 36.3%, the expenses attributed to drugs
42.2% and the clinical consultations and diagnostic
tests 22.5%. In the study using the bottom-up focus
the hospital costs represented 43% of the total,
drugs 40% and consultations and complementary
tests 17%. Despite the differences observed in the
absolute values between the two types of studies,
the distribution of the costs was very similar. If the
total direct cost of COPD is divided between the
total of the country population, health care for
COPD costs each citizen $13.32 annually. To put
this figure into perspective, a study carried out in
The Netherlands reported a cost of $23 per capita in
the association of asthma and COPD. The differ-
ences may be due to the inclusion of asthma in the
last study and a lower index of underdiagnosis in
The Netherlands, among others. Other studies car-
ried out regarding the cost of COPD in different
European countries are shown in Table I. 
All estimates indicate that the situation will not
improve in the near future. The impact of aging and
changes in smoking habits is responsible for an esti-
mated increase of more than 60% of total life years
loss and an increased loss of 75% of disability-
adjusted life years (DALYs) from 1990 to 2020 in
The Netherlands [20]. New projections performed
until 2025 provide similar results with an increase
in prevalence and costs of COPD despite the cam-
paigns against tobacco smoking [21]. 
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The cost of pharmacological treatment is steadily
increasing in all European countries. The main rea-
sons are expensive, new hospital treatments with
biological drugs and medications for cancer. The
other main reason is that the population segment of
elderly people is widening and with that the num-
ber of people with common chronic diseases
including COPD. The cost of COPD in Denmark
amounts to 10% of all health care costs. 
The annual cost of pharmacological treatment in
Scandinavia is today around €100 per inhabitant
(from newborn to old age included). The cost in
Denmark rose from about €2 billion in 2004 to €3
billion in 2008. This huge cost is mainly covered by
the public health system, some private insurance
and to a minor degree by the patients themselves.
This immediately results in several interested parties
involved in the actual use and choice of medica-
tion: i) health professionals (especially doctors and
nurses as well as clinicians and clinical pharmacol-
ogists), ii) the patients and patient organizations, iii)
the administrative systems with administrators,
health economists and politicians, iv) the pharma-
ceutical industry, and v) public opinion with journal-
ists and lobbyists.
A regulation by central guidelines, specific rules
and norms seems justified. There are massive differ-
ences between regions in the prescribing pattern of
drugs with the same effect and side effect profiles
but in some cases a 10-fold difference in cost. Such
unnecessary expense is obviously unwarranted
because the treatment effect is the same for a less
expensive drug. A ‘correct’ treatment can have an
unacceptably high cost. Regional guidelines are
therefore produced for the usual choice of a med-
ication in a specific class of drugs (inhaled cortico -
steroid and bronchodilators, anti-TNF, ACE
inhibitors, etc). These guidelines are publicized in
different ways and discussed with the health profes-
sionals. Other actions can be taken, e.g. withdrawal
of the reimbursement from specific drugs, which
makes the cost for the patient unacceptably high, or
imposing rules such as disallowing renewal of the
driver’s license to elderly people treated with benzo-
diazepines. In special cases an audit and personal
discussion with a doctor is arranged.
The general guidelines for handling a disease entity
are usually formulated by the scientific society, and
agreement about the general use of medication by
classes based on a step wise approach according to
severity is usually reached without problems among
specialists. However, when it comes to the specific
choice of a brand name, large differences in opin-
ion often flare up. This may be caused by personal
opinion about the effects of a specific medication
and/or by a lack of interest in the economic aspect
of drug use or the influence of the pharmaceutical
industry. This is the background for the establish-
ment of local pharmaceutical committees that
explicitly choose labelled drugs in a prioritized
sequence. This often occurs in the form of compro-
mises between specialists with different opinions
that have to find arguments for their choices.
A regulated practice has developed by law for phar-
maceutical substitution in the pharmacy. This means
that the pharmacy shall deliver another and cheaper
medication to the patient than the one written on the
prescription form, if the drugs contain the same
active substance, in the same amount and are used in
the same way. These are synonymous drugs and the
practice is possible as the National Medical agency
has made an evaluation. This means that the pharma-
cy gives the cheapest medication in almost all cases
only with a few exceptions (allergy to constituents,
the explicit wish of the patient or the prescriber for a


























Diseases increase in incidence and prevalence with
age, which makes the presence of comorbidities
very frequent. COPD is a very good example of a
disease with one or more comorbidities on account
of age and smoking as a common risk factor (osteo-
porosis, cardiovascular diseases, cancer) and com-
plications (depression and bronchiectasis). This is
the reason why patients are treated with polyphar-
macy, that carries with it the risk of drug inter -
actions. Patients with more than 5 drugs in their
treatment should have their medication explained
and reviewed for interactions.
Patients on inhaler treatment are all offered an eval-
uation of their inhaler technique and instruction in
correct inhaler use, in order to improve the efficacy
of inhaled medications and avoid waste due to inef-
fective inhaler technique.
Each country in Scandinavia has developed its own
reimbursement system, that comprises a common
part which applies to everybody and special rules
for patients in specific circumstances. The common
reimbursement scheme in Denmark is, roughly
speaking, that the first €115 spent for the purchase
of pharmaceutical drugs is not reimbursed (howev-
er, for age < 18 years, there is a 60% reimbursement
also of this cost segment provided). The % reim-
bursement increases gradually to 85% with pur-
chases above €400 in all age groups. However, per-
sons with chronic diseases pay up to a maximum of
€450 out of their own pocket, and will have all
additional cost covered. In special cases it is possi-
ble to apply for reimbursement of specific drug
treatments, to have additional cost cover if the per-
sonal economic situation requires, or special sup-
port for terminal care and treatments.
A special group of people are the illegal immi-
grants, who have no public or private insurance.
They experience serious problems when falling ill.
They can in principle only be treated for acute
severe disease and transported to their homeland as
soon as possible, whereas management of the cost
of chronic diseases is at their own total expense.  
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In Italy, as well as in other industrialised countries,
COPD still represents a major cause of morbidity
and mortality, and exerts a substantial burden on
health and the health care system. The “pharma-
coeconomic era” started around the end of the last
century and corresponded to the overall need for
“accountability”, and the economic evaluation of
interventional strategies progressively became the
crucial point aimed to support decision makers in
allocating the ever diminishing health care
resources. From 1979 to 2009, when compared to
overall international and European studies, the
Italian scientific literature in pharmacoeconomics
of COPD gradually increased from 2.0% to 4.1%,
and from 6.9 to 10.7% respectively. At present,
while USA is producing the highest number of stud-
ies in this field (43.2%), Italy ranks 7th in the inter-
national seeding (3.4%), and 4th in Europe (8.1%),
preceded by The Netherlands, UK and Spain. 
In Italy, the cost-of-illness of COPD was calculated
in 2002 for the first time: data were collected from
28 Lung Units, and the cost-of-illness analysis was
carried out within the framework of the NHS [1].
Mean cost/patient/year ranged from €1,500 to
3,912 according to the illness severity, and direct
costs (in particular, hospitalizations and ER admis-
sions) represented the main driver of cost.
Moreover, unacceptable levels for underdiagnosis
and mistreatment of COPD were also confirmed in
that study. In a further investigation [2], the mean
societal cost of COPD was €1308/p/y: as 75% of
cost was due to hospitalizations, a more effective
strategy for managing and controlling COPD exac-
erbations was further strongly recommended in
order to alleviate the burden of the disease in Italy.
A few years later, the economic value of different
therapeutic interventions (which were regarded as






























0 lines) was investigated by means of a markovian
model on the basis of their effectiveness in outcome
optimization [3]. The key message emerging was
that both a prompt diagnosis of disease and disease
exacerbations, together with an appropriate and
long-term therapeutic approach to COPD patients,
represent the most effective strategy to optimize all
outcomes related to the disease, and to substantially
reduce the impact of COPD on patient, healthcare
institutions and society as a whole. 
Two years ago, health resources consumption and
costs generated in 12 months by COPD were calcu-
lated on a national basis, in a real-life setting for a
1-year duration, and according to a bottom-up,
observational, prospective multicentric study. At the
end of the survey, outcomes were compared with
those of the previous year [4]. A total of 748
patients were recruited, and 561 were defined as
eligible by the Steering Committee; the proportion
of moderate and severe COPD was 53.7 and
16.8%, respectively. Mean total cost/p/y was
€2,723.7, ranging 913-5,452 according to the dis-
ease severity. At the end of the survey, requirement
of health services had dropped significantly com-
pared to baseline: GP visits by 57.4%; ER use by
12.5%; hospitalizations by 18.4%. Furthermore,
even if direct costs remained the main driver of
cost, the mean total cost per patient dropped by
21.7% (p < 0.002), mainly due to a much more
appropriate interventional and therapeutic strategy.
When compared to previous studies, these data pin-
pointed that the mean total cost/p/y of COPD dou-
bled in a 5-year period in Italy: this trend has also
been registered in different countries (such as USA)
over the same period. Quite similar figures were
found in another study carried out on 268 COPD
patients from different lung units [5]. 
Data from a recent cross-sectional study carried out
on COPD patients with different severity support
the evidence that also moderate COPD represents a
substantial economic burden for health care sys-
tems, and strongly indicate both the clinical and the
economic convenience of an earlier, long-term ther-
apeutic intervention in these circumstances [6]. To
identify more incisive strategies for controlling
COPD and minimizing related health care expendi-
ture, cost-effectivenes and cost-utility models with a
longer time-horizon should be adopted in future
studies.
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The AGE.NA.S (National Agency for Regional
Health Services) has, among its other activities, the
responsibility at national level for the elaboration
and dissemination of clinical and organizational
guidelines. The strategic use of guidelines permits
the evaluation of the quality of the services based
on scientifically valid principles, recognizable by
operators and decision makers. In fact guidelines
constitute a primary source for the identification of
indicators which can contribute in the assessment
of appropriateness and they are a means of commu-
nication among professionals and of information to
citizens. 
Guidelines have been criticized for how they rate the
quality of evidence and the strength of recommenda-
tions, although with the development of systems
such as GRADE - Grading of Recommendations
Assessment, Development and Evaluation - this
limit has been overcome. Concerns now remain
about the necessity of elaborating ad-hoc initiatives
for the correct implementation of guidelines at
national and local (regional) level. For some clinical
conditions limited information is available about


























between current practice and guidelines regarding
the use and selection of treatments have been found. 
Alongside this comes the razionalization of the use
of health resources and the choice of diagnostic and
therapeuthic paths according to priorities which
should be established on the basis of the best avail-
able evidence. Therefore, in the development of
guidelines efforts should be addressed to the exam-
ination and selection of interventions with a cost-
effective profile.
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Reports estimate that, by the year 2020 COPD will
have moved up, becoming the third leading cause
of death worldwide. These astonishing statistics
make it extremely important to identify risk factors
associated with COPD and seek early treatment if
symptoms arise. This is crucial as presently most
people are not diagnosed until they are in their late
50s when a decline in their respiratory lung func-
tion has already set in [1]. 
Recognizing COPD risk factors and advocating
lifestyle changes is the best way to maintain optimal
respiratory health and prevent this devastating, life-
threatening illness. Population-based and clinical
studies have identified risk factors for COPD [2].
These can be divided into factors responsible for
COPD exacerbations and factors responsible for
COPD development. However, some factors are
responsible for both the development and the exac-
erbations. Factors responsible for lung function
impairment (which starts already during lung func-
tion growth), a main feature of COPD, have also to
be taken into account.
Lifestyle modifications that can help prevent COPD,
or improve lung function in COPD patients,
include: quitting smoking, avoiding respiratory irri-
tants and infections, avoiding allergens, maintain-
ing good nutrition, drinking lots of fluids, avoiding
excessively low or high temperatures and very high
altitudes, maintaining proper weight, and exercis-
ing to increase muscle tone. However, data are
insufficiently evidence-based for some factors. 
Robust data exist, although to different extents, on
active and secondhand tobacco smoke exposure,
occupational exposure and outdoor and indoor air
pollution [3]. Smoking is the leading cause of
COPD. For instance, the American Lung
Association estimates that 80 to 90% of those diag-
nosed with COPD are chronic smokers. The amount
an individual smokes as well as how long they have
been smoking can increase the probability of devel-
oping the disease and intensify its severity. Risk fac-
tors are not only prevalent in those who smoke reg-
ular cigarettes, but exist for pipe and cigar smokers
as well. Quitting smoking is the most important
thing that one can do to prevent or slow damage to
the lungs. Although it is not possible to undo the
damage that smoking has already caused, further
lung damage can be prevented by quitting. In terms
of disease progression, other factors of COPD
besides direct smoking that may also influence the
course of the disease and its eventual health out-
comes as well as the development, include second-
hand smoke (SHS) exposure and occupational
exposures [3]. Actually, an estimated 25-45% of
patients with COPD have never smoked. The bur-
den of non-smoking COPD is therefore much high-
er than previously believed. 
Avoiding conditions that may irritate the lungs can
reduce breathing problems in people with COPD.
These conditions include indoor and outdoor air
pollution; smog; cold, dry air; hot, humid air; or
high altitudes. 
SHS exposure is an important factor influencing dis-
ease severity and health status in COPD [4].
Previous studies suggest that SHS exposure may be
a cause of new-onset COPD or impaired pulmonary
function. The effect of SHS exposure on persons
with established COPD, however, has received little
attention. Because SHS is a modifiable risk factor,
clinicians should assess SHS exposure in their
COPD patients and counsel its avoidance. In public
health terms, the effects of SHS exposure on the vul-
Session III: Inappropriateness at different steps of COPD
management  






























0 nerable subpopulations including COPD patients
should provide a further rationale for laws prohibit-
ing smoking in public. 
Various studies have reported that exposure to toxic
gases in the workplace, grain dust in farms, and dust
and fumes in factories is strongly associated with
COPD. In 2003, results of a systematic epidemio-
logical review into occupational factors associated
with COPD by the American Thoracic Society
showed that about 15% of COPD cases might be
attributable to workplace exposure [5]; and a sub-
sequent follow up provided similar estimates [6].
Use of appropriate protective gear (e.g. face mask)
in the workplace to avoid inhaling hazardous sub-
stances has also been documented as potentially
relevant. 
Exposure to indoor and outdoor air pollutants con-
tinues to be a major contributing factor to augment-
ed morbidity, healthcare resources utilization and
higher mortality among patients with COPD [7],
particularly in the elderly [8], subsequently impact-
ing public health, but there are few studies on
whether air pollution is a key factor in the develop-
ment of this disease. About 3 billion people, half the
world’s population, are exposed to smoke from bio-
mass fuel compared with 1.01 billion people who
smoke tobacco, which suggests that exposure to
biomass smoke might be the biggest risk factor for
COPD globally. Byproducts of oxidative stress
found in air pollutants are common initiators or pro-
moters of the damage produced in such chronic dis-
eases. Such air pollutants include: ozone, sulfur
oxides, carbon monoxide, nitrogen oxides, and par-
ticulate matter. Interaction between oxidative stress
byproducts and certain genes may modulate the
expression of COPD. 
Strong evidence exists also for infections as a trigger
of COPD exacerbations. Avoiding respiratory ill-
nesses, such as influenza and pneumonia, can
decrease the risk of COPD worsening [9]. Although
clinical trial data are limited, vaccinations can pre-
vent some of the infections that cause COPD exac-
erbations and should be administered to all patients
with COPD. Vaccines do not cause exacerbations of
COPD. Patient and physician barriers to vaccination
have to be overcome with targeted education and
system-wide interventions. 
Lastly, physical activity has been shown to improve
lung health [10]. Airflow obstruction leads to pro-
gressive hyperinflation, activity limitation and phys-
ical deconditioning. Thus physical inactivity is an
important therapeutic target in COPD. Targeting the
airflow obstruction with therapy in conjunction
with a supervised exercise prescription is currently
the most effective therapeutic intervention in earlier
COPD. Other important manifestations of skeletal
muscle dysfunction include muscle atrophy and
weakness. However, data on these physical effects
are still scant.
The challenge we will all face in the next few years
will be to obtain more robust data on risk factors for
COPD development, progression and exacerbation
and to implement cost-effective prevention and
management strategies to stem the tide of this dis-
ease and its cost.
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While the diagnosis of asthma requires symptoms,
the diagnosis of COPD has often been based only
on spirometry, given the presence of a provoking
factor such as smoking or atmospheric pollution or
occupational exposure [1]. Recently, the impor-
tance of adding medical history data to spirometry
has been emphasized as there is still considerable
underpresentation and underdiagnosis of COPD
and also as family physicians focus on presented
symptoms. Thus, diagnostic guidelines should stress
the importance of persistent cough and phlegm to
support timely diagnosis of COPD in family prac-
tice [2]. 
Another important point is that the GOLD
Committee suggested the use of a fixed FEV1/FVC
cut-off of 0.70 instead of the more appropriate sta-
tistically defined lower limit of normal (LLN), claim-
ing that the fixed ratio is easy to remember and to
apply and not dependent on the choice of reference
equation. Many recent papers have documented
that the fixed cut-off of 0.70 significantly overesti-
mates airflow obstruction in older people leading to
misdirection of resources, unnecessary costs, and
individual and societal harm [3-5]. On the other
hand, it underestimates airflow obstruction among
young adults leading to a missed opportunity for an
early diagnosis of COPD in patients who are more
likely to benefit from intervention [3]. Since diag-
nostic confusion between COPD and asthma
appears common, bronchodilatation performed
after spirometry may help to reduce the chance of
misclassification. 
The complexity and heterogeneity of the disorders
encompassed by the term COPD with the overlap
of different phenotypes have recently led to recom-
mendations: i) that a new taxonomy is required to
better define the disorders of airways obstruction
and, consequently, ii) that clinical assessment
should become increasingly multidimensional [6-
7]. Among lung function parameters, besides
FEV1/FVC, lung volumes should always be included
in the diagnosis of COPD as evaluation of hyper -
inflation is an important criterion in the phenotyp-
ing of COPD patients. 
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It is generally accepted that COPD is not only pre-
ventable but also treatable. This change in concept
from a previously nihilistic treatment paradigm
based on smoking cessation being the only possible
treatment for COPD has occurred over the last 2
decades as a consequence of several large trials
including not only pharmacological agents but -
equally important - pulmonary rehabilitation and
even surgery (lung volume reduction surgery). It is
inherent to these trials that patients be included
only if they have COPD and by and large are free of
concomitant morbidities that can impact negatively
on the trial outcome, thus restricting the value of the
results as the population is highly selected. On the
other hand, once the results of the trials become
available and, usually out of necessity, the findings
permeate the larger community and patients get
treated whether they meet the original inclusion
and exclusion criteria or not. 
It is in this stage of the implementation of therapies
on a greater scale that treatments have to be moni-
tored as to their safety and their likelihood to pro-
vide efficacy, thereby avoiding undue side effects
and negative consequences. 
In the specific case of COPD, the problem is com-
pounded by the fact that these patients are frequent-
ly afflicted by multiple co-morbid problems. Heart
disease, osteoporosis, peripheral muscle weakness
and dysfunction, anemia, depression, anxiety and
lung cancer are more frequent in patients with
COPD than in the population at large. It is then
imperative that safety be carefully determined in
observational registries so that in the end a compos-
ite analysis of trial results is interpreted in the light
of empirical usage. Following is an overview of the
available evidence for the most frequently used
treatments.
Pharmacological treatments
Recently there has been concern that the long-term
use of inhaled bronchodilators commonly used in
the treatment of COPD, including long-acting 
β2-agonist (LABA) and anticholinergic drugs, may
increase the risk of cardiovascular complications.
However, prospective data on the relative risk of
therapy in patients with sufficient symptoms to be
offered treatment with these drugs has, until recent-
ly, been lacking.
Anticholinergics
The safety profile of inhaled anticholinergics has
been studied for many years. The short acting ipra -
tropium bromide has been available to patients for
over 20 years, and tiotropium since 2002. An asso-
ciation between ipratropium and cardiovascular
mortality was noted in an earlier report from the
Lung Health Study. However, a re-analysis of the
same data by Lanes et al. showed that the increased
risk of cardiovascular morbidity and mortality in
that study was concentrated among patients who
were randomized to the ipratropium group but who
did not take ipratropium. Several reports have retro-
spectively examined safety data using different
approaches with somewhat conflicting results
regarding a possible association between inhaled
anticholinergics, including tiotropium, and adverse
cardiovascular consequences. In the first one, Lee
et al. examined the association between various
respiratory medications and risk for death in newly
diagnosed COPD patients based on a retrospective
nested case-control study using various databases.
The authors concluded that ipratropium was associ-
ated with increased cardiovascular deaths, whereas
inhaled corticosteroids were associated with
reduced risk. The authors were limited by the data
available to them, which did not include informa-
tion on smoking or lung function. All-cause mortal-
ity risk ratio was 1.02 for ipratropium. The second
analysis, by Singh et al., selected randomized con-
trolled trials of any inhaled anticholinergic for treat-
ment of COPD that had at least 30 days of treatment,
and reported on cardiovascular events. The primary
outcome was a composite of cardiovascular death,
myocardial infarction, or stroke. The secondary out-
come was all-cause mortality. While the report
describes ipratropium and tiotropium trials both
combined and separately, no differences in any car-
diovascular effects would be expected between the
two compounds based on their pharmacology.
Singh et al. concluded that inhaled anticholinergics
significantly increased the risk of the composite car-
diovascular endpoint, myocardial infarction and
cardiovascular death without a statistically signifi-
cant increase in the risk of stroke. The analysis did
not take into account differential discontinuation
(i.e. in most of the trials, more patients in the place-
bo group prematurely discontinued the study than
did patients taking active medication and were
therefore followed for briefer periods of time during
which adverse events were reported) and differ-
ences in exposure. The recent analysis of the large
tiotropium database and the findings of the
prospective UPLIFT study indicate a reduced risk for
mortality from cardiovascular events and even over-
all mortality in patients receiving tiotropium. The
mechanism by which tiotropium may reduce these
events and improve survival cannot be precisely


























an association with respiratory events must be con-
sidered given the significant reductions in exacerba-
tions and hospitalizations observed. In the pooled
analysis of 30 trials, tiotropium treatment also
resulted in significant reductions in serious adverse
events under the cardiac and respiratory organ sys-
tems. There are recognized limitations to pooling of
clinical trial data. There are differences in popula-
tions, study design, duration of trials, collection of
data and the ability to adjust for differences in expo-
sure. 
β-agonists
Like the antimuscarinic agents, β-agonists have the
potential to precipitate cardiac rhythm disturbances
and other cardiac events; however, this has not
been regarded as important in clinical practice until
recently. Unfortunately, unlike the situation for car-
diovascular disease, most studies of drug treatment
in COPD have been relatively brief (1 year and less)
and have only reported on-treatment data. As the
TORCH study was conducted in a patient group
likely to be prescribed inhaled LABAs, that dataset
addresses some of the problems inherent in these
earlier analyses. 
TORCH is the largest and longest prospective trial
to examine the role of an inhaled LABA and an
inhaled corticosteroid in COPD. Half of the over
6,000 patients were randomised to a regime con-
taining SAL and, allowing for dropouts, this provid-
ed 7,231 patient-years of exposure to these agents.
Over the 3 years, approximately 1 in 5 patients
experienced a cardiovascular AE. The event rate
was lowest in those receiving SAL in combination
with FP, and not different from those patients treated
with placebo or with LABA monotherapy. A SAE
requiring hospitalization and new cardiovascular
ischaemic events were approximately half as com-
mon as the total cardiovascular event rate, but there
was a similar pattern across treatment groups.
Seven percent of patients had a history of previous
MI. In this group the cardiovascular event rate, as
would be expected, was higher. Again, no trend
was seen for more AEs in those patients randomized
to treatment with SAL in combination with FP.
However the data for SAL alone are inconclusive,
possibly due to the small sample size in this smaller
subgroup of patients.
Unlike other COPD studies, TORCH developed a
rigorous methodology for determining the likely
cause of death, which was adjudicated by an expert
panel blinded to the study medication. Moreover,
there was effectively complete follow up of the vital
status of all patients 3 years after randomisation. The
patients randomised to LABA alone had the lowest
rate of cardiovascular death, while those who
received placebo had the largest number of events.
The number of on-treatment deaths, analogous to
data included in earlier COPD studies, showed a
similar pattern across treatments. 
A range of predictable factors increase the cardio-
vascular event rate, including: greater age, a history
of previous cardiac disease, and worse lung func-
tion. None of these factors interacted with treatment
to identify a specific ‘at risk’ group. 
Inhaled corticosteroids
If cardiovascular events are the most feared compli-
cations of patients receiving treatment with anti-
cholinergics or β-agonists, the recent documenta-
tion that the risk of pneumonia is increased in
patients receiving inhaled fluticasone has arisen
from well controlled randomized trials. Based on
the findings reported in the TORCH trial Ernst and
colleagues reported the results of a nested case-
control study within a cohort of nearly 176,000
patients with COPD that examined ICS use and the
risk of hospitalization for pneumonia. Compared
with non-ICS users within the past year, patients
receiving at least 1,000 mcg/day of FP equivalent
had a rate ratio for pneumonia hospitalization of
2.25 (95% CI 2.07– 2.44). In addition, the length of
pneumonia hospitalization was similar whether or
not patients were current users of ICS (mean 11.7
days vs. 11.8 days), as was all-cause mortality with-
in 30 days of being hospitalized for pneumonia for
patients dispensed ICS in the prior 2 months (8.2%
of 18,005 patients) compared with those who were
not dispensed ICS (7.4% of 5,937 patients). The
careful review of all deaths reported in the large
TORCH trial showed no difference in pneumonia
mortality between patients receiving inhaled corti-
costeroids and those not receiving them. 
What is very remarkable in the whole arena of phar-
macological therapy is how much we have learned
in the process. Medications have been shown to
improve lung function, health status, decrease
exacerbations and perhaps even impact on mortal-
ity but this has come at a price. Indeed, there is not
only an economic cost but also the development of
side effects that need careful monitoring over time.
Fortunately, society has developed mechanisms by
which the effect of drugs is monitored closely and
even if not all problems can be prevented, it has
made the agents available much safer to use.
Non-pharmacological therapies
The implementation of the National Emphysema
Trial (NETT) was a first for the evaluation of surgical
therapies. NETT represented the first surgical proce-
dure subjected to a randomized trial using a med-
ical comparator, in this case optimal medical thera-
py including pulmonary rehabilitation. Perhaps the
greatest teaching to be derived from this study relat-
ed to the initial report from the group. That publica-
tion dealt with the characterization of patients who
had poor outcome when subjected to lung reduc-
tion surgery. Indeed, in the initial evaluation and
follow up of the patients included in NETT, it
became evident that a very low FEV1 and diffusion
capacity for carbon monoxide (DLCO) were associ-
ated with a very poor outcome. Indeed, these obser-
vations had important consequences for the field
because they became reasons to exclude patients
from consideration for lung volume reduction pro-






























0 assessment of new technologies, in this case for
patients with COPD.
Perhaps a word of caution must be raised because
alerting to the negative effects of a treatment prior
to a full evaluation of the pros and cons of treat-
ments may lead to premature killing of good ideas
and therapies.
The last therapy that has generated great interest is
that of pulmonary rehabilitation. Several modest
size trials have been conducted but they have all
emphasized the beneficial consequences of the
therapy with very little information regarding bad
outcomes or side effects. Perhaps, the most relevant
information related to negative outcome is that of
providing a picture of patients who do not want to
participate in rehabilitation and, equally important,
of how many do not complete the programs. The
percentage of patients who do not join programs
hovers around a very high 60% and out of those
that join close to 30% fail to complete the program.
Unfortunately very little has been done to better
characterize those patients and evaluate the factors
that lead to lack of compliance and uptake.
Conclusions
Much has been learned about the inappropriateness
of therapies through the implementation of the sci-
entific method. Even though it may seem slow and
complex, it is evident that application of these con-
cepts in the area of treatment has enhanced our
knowledge about the therapies that we provide to
patients. As we enhance our armamentarium, it is
important to remember that our current approach
has served us well. We have indeed gained know -
ledge and confidence that the most frequently used
therapies are safe and effective while we continue
to investigate newer avenues to further empower
our patients with a better future.
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COPD is believed to become, in a few years, the
third leading cause of death worldwide.
Exacerbations of COPD are a frequent cause of
emergency department visits and hospitalizations.
An exacerbation of COPD is defined as a change in
the patient’s baseline dyspnea, cough, and sputum
that is beyond day-to-day variations, is acute in
onset, and may warrant a change in regular medica-
tion [1]. Exacerbations of COPD are common and
present a major financial burden for most health
care systems. The management of patients experi-
encing an acute exacerbation varies despite guide-
line-recommended care. Furthermore, there is little
information on how to manage patients after hospi-
talization for COPD in order to optimize care and
reduce the occurrence of a relapse [2]. Indeed, after
an emergency department visit for an exacerbation
of COPD there is a high probability that a new
episode will occur in the first 2 weeks after dis-
charge [3,4]. Exacerbations are not random events
but the risk of recurrence is greatest within the first
few weeks of the initial event [5]. 
Several risk factors have been identified that facili-
tate the occurrence of a new exacerbation, includ-
ing: number of previous exacerbations, use of oxy-
gen, lung function, absence of a primary caregiver
and choice of pharmacological therapy [6,7]. For
instance, patients who lack a primary caregiver use
emergency care services more frequently than those
who have a primary caregiver [8]. 
The lack of literature makes it impossible to provide
specific recommendations for the management of
patients after exacerbations of COPD. The use and
value of spirometry, the potential benefit of home
monitoring and of noninvasive ventilation as well as
the value of long-term oxygen therapy, self-manage-
ment programs and early rehabilitation need to be
better investigated. Current guidelines recommend
a follow up at 4–6 weeks after hospitalization in
order to assess clinical status, inhaler technique, the
need for long-term oxygen therapy and FEV1. It is
not clear whether a follow up earlier after discharge
could reduce the exacerbation rate. There are few
studies comparing the effect of a different frequency
of follow up visits on the relapse rate of patients
after hospitalization due to a COPD exacerbation.
Available data suggest that an early rehabilitation
intervention should be included in the follow up
program. Rehabilitation is advisable after an acute
exacerbation because it reduces the hospitalization
rate and improves exercise capacity and quality of
life [9]. 
In conclusion, although the current literature does
not provide clear recommendations regarding all
the components of a care plan following an exacer-
bation of COPD, a rehabilitation program should be
included. Efforts should be made to improve the
availability of rehabilitation for COPD patients in
different health care settings. 
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COPD is a severe multifactorial pulmonary disorder
whose pathogenesis is not completely understood.
Interestingly, a gradual shift from “inflammatory-
based” pathogenic theories to more complex
approaches has occurred in recent years [1].
Striking new evidence regarding the pathogenesis
of COPD (in particular, emphysema) relates to its
proposed inclusion within the category of diseases
of “premature aging” of the lung, based on strong
similarities with diseases characterized by telomere
and stem cell dysfunction [2-4]. In the lungs, telo -
mere erosion can variably affect the renewal poten-
tial of different stem cells, thus causing progressive
depletion of relevant parenchymal components
eventually culminating in alveolar loss and func-
tional abnormality. 
Interestingly, evidence is accumulating that also
idiopathic interstitial pneumonia (IPF) can be
included in the pathological category of diseases
characterized by “telomere dysfunction” [5-7].
Tobacco smoke is a key pathogenic element in both
COPD and IPF, and may serve as an environmental
co-factor for the development of both diseases [5].
But how can this proposed similarity between the
basic pathogenic mechanisms underlying COPD
and IPF be reconciled with the obvious diversity of
their pathologic and clinical presentations? The
explanation could be sought in the heterogeneity of
the underlying genetic alterations, as well as in the
diversity of specific cell targets. Several reports in
fact suggest that in IPF the major target is the alveo-
lar epithelial stem cell (type II pneumocyte) [8]
whereas in COPD mesenchymal cells (fibroblasts
and endothelial cells) within the alveolar parenchyma
represent the Achille’s heel [9]. Thus, in COPD,
abnormal apoptosis, senescence and loss of func-
tion mainly affect cells involved in the production
of extracellular matrix proteins (elastin, fibronectin,
etc.), with eventual weakening of the mesenchymal
structure of the alveoli, leading to a defect in tissue
reserve and “vanishing” of the supporting scaffold
for epithelial cells. 
Although some evidence has been provided of
pneumocyte apoptosis, alveolar reparative mecha-
nisms seem to be absent in emphysema, with no
evidence of pneumocyte proliferation. The com-
plexity of genetic predisposing features (e.g. telo -
mere stricture together with alpha-1-antitrypsin
deficiency, VEGF insufficiency, and/or others) work-
ing in concert with environmental factors may
explain why mesenchymal progenitors are more
profoundly affected in these patients. Accordingly,
in emphysema tobacco smoke can severely affect
mesenchymal function and repair, and senescence
related markers are mainly demonstrable in fibro -
blasts and endothelial cells. 
In conclusion, this evolving scenario opens up new
possibilities for a better understanding of the patho-
genic mechanisms of COPD and also IPF, and may
yield new perspectives for alternative treatments of
these devastating diseases acting on either pharma-
cological protection or specific replacement of
affected stem cells [10]. 
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A rapidly evolving scenario
Ageing of the population together with changes in
lifestyle are central factors explaining the increasing
prevalence of chronic disorders, which is expected
to continue over the next decade leading to further
dysfunctions of healthcare systems worldwide [1-
3]. The urgent need to introduce substantial
changes in the delivery of care for chronic patients
is widely acknowledged. The World Health
Organization (WHO) has launched the Innovative
Care for Chronic Conditions (ICCC) initiative [4]
formulating basic principles and strategies to
enhance management of chronic patients [5,6]. 
There is evidence that information and communica-
tion technologies (ICT) can play an enabling role
over the whole range of services, from life-style and
self-management of health to improving health
related quality of life of patients and citizens as well
as managing chronic disease conditions [7].
Moreover, properly designed innovative health serv-
ices supported by ICT might have a positive impact
on chronic disease modulation and prognosis. 
Despite the many advances and accepted potential
of technology, ICT adoption in healthcare has
lagged behind. The barriers originate at different
levels and are associated to a multitude of techno-
logical, cultural, legal, and market related factors.
Adoption of ICT in healthcare is currently a major
priority in Europe as shown by the major e-health
deployment initiatives (e.g. epSOS) launched
through the Competitiveness and Information
framework Program (CIP) [8,9]. 
From management of crisis to integrated care
A recent analysis of the burden of all chronic con-
ditions on tertiary care hospitalizations [10] indicat-
ed the need for revisiting managerial aspects of
exacerbated chronic patients with a broad scope
aimed at enhancing not only efficacy of care during
the exacerbations, but also preventing admissions
due to severe exacerbations in frail patients. In view
of the high social and economic burden generated
by hospitalization of patients with chronic disor-
ders, new care modalities aimed at decreasing
admissions through patients’ empowerment and
implementation of alternatives to conventional hos-
pitalization have been developed in recent years
[11-12]. It is of note, however, that a holistic
approach of integrated care in chronic patients
should not be focused only on prevention and/or
management of crisis. Instead, principal targets
should be early diagnosis and prevention together
with future personalized care strategies launched at
early stages aimed at modulation of disease
progress and enhancement of prognosis. Successful






























0 a progressive decline of the classical disease man-
agement approach towards new patient-oriented
strategies including the adoption of a new health
paradigm fitting the needs of chronic care, as pro-
posed by the Chronic Care model [1-6].
Changes in lifestyle aimed at disease prevention
and promotion of well being, empowerment of
patients and relatives in self-management together
with share care arrangements among the different
levels of care are all necessary elements to improve
efficiency of chronic care. 
There is no doubt that current fragmentation among
levels of care and community services constitutes a
major limiting factor for a practical adoption of the
principles formulated in the Chronic Care model.
Moreover, management of comorbidity is a major
challenge often overlooked by evidence-based
diagnosis and treatment using disease-specific clin-
ical guidelines.
Several disease-specific randomized controlled tri-
als undertaken in patients with chronic heart fail-
ure, COPD, diabetes and other disease conditions
have consistently shown the potential of integrated
care to enhance clinical outcomes while generating
cost-containment at system level. A common prob-
lem in all these pilot studies is that disease-specific
trials have shown high internal validity but a ques-
tionable external validity because of an elevated
rate of exclusion mainly due to severe comorbid
conditions (~ 60% of cases) that could potentially
be managed through transversal programs
addressed to frail patients with multiple severe
chronic disorders. The second most important
exclusion factor, often present in frail patients, is
lack of appropriate social support. As suggested
above, there is a strong need to move the focus from
the current interest in advanced chronic conditions
toward the development of preventive integrated
care strategies addressed to early stages of chronic
diseases or even to citizens with high risk of devel-
oping chronic disorders. The ultimate aim should
not be constrained to management aspects, but
should be to achieve a positive modulation of the
prognosis of chronic disorders. Note, however, that
highly standardized interventions together with
continuous evaluation of results will be required. 
In order to face all these challenges, more and more
attention is being paid to the evolution of health
systems from a provider-centered perspective to a
patient-focused approach. In the integrated care
scenario being deployed in the NEXES “Living
healthily at home” project, chronic patients includ-
ed in well standardized care programs are managed
through a support center (multimedia call center) to
enhance accessibility to the specific type of care
needed (Figure 1). Major organizational adjust-
ments of health systems combined with significant
educational changes are urgently needed in order
to prepare the healthcare professionals for new and
evolving roles. Moreover, there needs to be a major
adjustment of financial modalities for the services to
ensure sustainability of integrated care supported
by ICT. 
Extensive deployment of integrated care service
NEXES is the acronym of the project “Supporting
Healthier and Independent Living for Chronic
Patients and Elderly” conceived to face the transi-
tional phase from existing pilot experiences to
deployment of health/social services targeting
selected groups of patients. It supplements and/or
represents an alternative to existent conventional
approaches. The project grew from the need to
unfold previous pilot experiences on innovative
healthcare services supported by ICT, already men-
tioned above. The main objective is to evaluate the
potential for generalization of four specific services
(see below) targeting citizens at risk and patients
with chronic illnesses. NEXES will mainly address
patients with one or more of the following chronic
conditions: COPD, chronic heart failure and dia-
betes type II. 
In this scenario, ICT plays a fundamental support
role in the new health model. The services to be val-
idated through randomized controlled trials will be
carried out in large scale studies including approx-
imately 5,000 patients. The four types of services
indicated below cover the needs of a broad spec-
trum of health problems, from those affecting citi-
zens at risk or with early disease to those addressing
frail patients with advanced chronic disorders. 
1) Wellness and rehabilitation aimed at promoting
healthy lifestyles in clinically stable chronic
patients and enhancing their self-management 
2) Enhanced care for frail patients to prevent
unplanned hospitalizations 
3) Home hospitalization of chronic patients with
severe exacerbations aimed at optimization of
home hospitalization
4) Support to diagnosis and/or to therapeutic proce-
dures including collaborative tools for profes-
sionals working at different healthcare levels to
enhance their potential for action in home-based
interventions.
All services will be assessed at three distinct sites
FIGURE 1: INTEGRATED CARE SERVICES AS DEPLOYED IN THE
NEXES PROJECT
• Target patients
• Management by programs









































(Barcelona, Central Norway Region and Athens)
notwithstanding some existing differences in the
specifics of healthcare organization. The impact of
heterogeneities among sites will be evaluated. The
differences among sites may offer opportunities for
planning of co-developments at cross-border level
in the deployment phase. One of the primary objec-
tives of NEXES is to provide robust results to health
technology assessment agencies and to decision
makers in order to facilitate the extensive deploy-
ment of the services and the sustainability of the
care model. 
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COPD is a multicomponent disease with inflamma-
tion at its core, in which patients experience pro-
gressively worsening lung function, disease symp-
toms and quality of life, as well as increasing exac-
erbations. The therapeutic challenge presented by
COPD arises from the need to target all compo-
nents of the disease. In recent years a number of
large clinical trials have been carried out aimed at
answering major questions on the long-term man-
agement of COPD.
These clinical studies have been mainly addressed
to clarify the following open questions:
- what is the best maintenance therapy from GOLD
III to IV treatment?
- is earlier intervention important for COPD treat-
ment?
- do bronchodilators have an impact on COPD
mortality?
COPD is a treatable disease and the long-acting
inhaled medications for bronchodilation in COPD
include long-acting anticholinergics and long-act-
ing β2-agonists. Each has shown to improve FEV1 by
a mean of approximately 150–250 ml more than
placebo. These agents also significantly improve
health-related quality of life. Meta-analyses have
demonstrated that these long-acting inhaled med-
ications are associated with significant reductions
(20–26% per year) of acute exacerbations of COPD.
In addition to pharmacological therapy, patients
with moderate to very severe COPD have been
shown to benefit (improved health status, quality of
life, and exercise tolerance) from participation in a
pulmonary rehabilitation program. In COPD
patients with chronic, resting hypoxemia, use of
supplemental oxygen for > 15–18 hours per day has
been shown to improve mortality. 
Finally, very severe COPD patients may benefit
from lung volume reduction surgery, which
improves health-related quality of life and exercise
tolerance in patients with FEV1 < 30% predicted
and mortality in carefully selected patients with
upper lobe bullae and low exercise capacity. Lung
transplantation is another potential option for
COPD patients without significant comorbidities
but with extremely limited functional status, to






























0 COPD is a reversible disease if patients receive
appropriate therapy. The reversibility relates to exer-
cise capacity and QoL. High on the list of specific
complaints that contribute to poor QoL in COPD
patients is intolerance concerning everyday activi-
ties (due to abnormalities in lung mechanics and
gas exchange, and to dysfunction of the ambulation
muscles). Bronchodilator therapy and supplemental
oxygen have been shown to improve exercise toler-
ance in the COPD patient and pulmonary rehabili-
tation is acknowledged to be the most successful
intervention for improving exercise capacity. 
A recently published evidence-based analysis con-
cluded that the highest grade of evidence supports
the inclusion of endurance and strength training as
well as upper extremity exercise and that rehabilita-
tion programs reduce dyspnea and improve QoL.
Current research is seeking to find ways to increase
the duration of benefit of pulmonary rehabilitation
and to determine whether rehabilitation imparts a
survival benefit.
Another important issue is the role played by early
intervention. In fact COPD in its early stages (stages
I and II) is usually not recognized, diagnosed or
treated, and therefore it may not be included as a
diagnosis in a patient’s medical record. Earlier inter-
vention therefore refers to early recognition, diag-
nosing, and treating of all COPD patients requiring
management (i.e. treatment) according to interna-
tional recommendations. Why intervene earlier?
Because significant lung damage may exist even in
“early” disease, as defined by lung function, when
patients may be ‘impaired’ but deny or under-per-
ceive their symptoms and functional impairment.
Treatment can be shown to improve function in
patients when disease is at an earlier stage and it
can impact the clinical course of COPD
About the impact of bronchodilators on COPD mor-
tality, the TORCH study showed a reduction in
death from all causes among patients with COPD in
the combination therapy group, though this did not
reach the predetermined level of statistical signifi-
cance. The UPLIFT study showed that tiotropium
improves the natural history of COPD patients
reducing mortality by approximately 11-16% and
FEV1 decline in GOLD stage II patients.
In conclusion, the experience emerging from large
clinical trials carried out in recent years in over
40,000 COPD patients per year/experience indi-
cates a sustained improvement in lung function,
quality of life, exercise capacity, decreased frequen-
cy of exacerbations and mortality through the long
term use of bronchodilators. In addition to these
data we have further evidence that long acting
bronchodilators should be used in patients with
moderate (GOLD II) disease, improving lung func-
tion and impacting the clinical course of the dis-
ease.
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